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1 ABERRANT EXPRESSION AND
TGF-BETA-DEPENDENT REGULATION OF ADAM23
mRNA IN HUMAN PANCREATIC CANCER CELLS
Ringel J1, Jesenowski R1, Batra S2, Fleig W3, Lo¨hr M4, (1) Section
Molecular Gastroenterology, German Cancer Center, Heidelberg,
Germany; (2) Department of Biochemistry, UNMC, Omaha, NE,
USA; (3) Department of Medicine I, University of Halle, Halle,
Germany; (4) Department of Medicine II, Medical Faculty
Mannheim, University of Heidelberg, Mannheim, Germany
INTRODUCTION AND AIM: Recently we have shown the
aberrant expression of ADAM17 in pancreatic cancer. ADAM23,
another member of this family, was found to be expressed during
brain development and in brain neoplasia. It plays an important
role in cell–cell and cell–matrix interactions. Here we investigated
ADAM23 mRNA expression in pancreatic cells and tissues.
PATIENTS AND METHODS: The expression of ADAM23
mRNA in 8 normal pancreas tissues (NP), 8 pancreatic cancer tissues
and 9 pancreatic cancer cell lines was analyzed by RT-PCR. The
regulation of ADAM23 mRNA was investigated in vivo and in vitro.
Therefore, pancreatic cancer cells were injected orthotopically
and subcutaneously using an established mouse model. RESULTS:
ADAM23 mRNA was detectable in 6/8 pancreatic cancer tissues
and 7/9 pancreatic cancer cell lines but in none of the normal
pancreas tissues. ADAM23 mRNA was down-regulated in sub-
cutaneous pancreatic tumors, whereas it was unaffected in tumors of
orthotopically implanted pancreatic cancer cells. First experiments
showed an ADAM23 mRNA induction in TGF-beta1 transfected
Panc1 cells. CONCLUSION: Our results demonstrate for the first
time an aberrant mRNA expression of ADAM23 in a non-brain
malignancy. Published data showed the involvement of ADAM23
in adhesion processes by the interaction of ADAM23 with integrins.
Our mouse model data suggest an environment-dependent regu-
lation mechanism for the ADAM23 expression. TGF-beta1, which
is known to play an important role in pancreatic cancer, might
be a regulation factor. This might be critical for invasion and
metastasis.
2 LOSS OF BNIP3 EXPRESSION IS A LATE EVENT
IN PANCREATIC CARCINOGENESIS CONTRIBUTING
TO CHEMORESISTANCE AND WORSE PROGNOSIS
Erkan M1, Kleeff J1, Esposito I2, Giese T3, Ketterer K1, Bu¨chler M1,
Giese N1, Friess H1, (1) Department of General Surgery;
(2) Institute of Pathology; (3) Institute of Immunology,
University of Heidelberg, Heidelberg, Germany
INTRODUCTION AND AIM: Altered expression of apoptosis-
regulating genes plays an important role in the aggressive growth
behavior and chemoresistance of pancreatic ductal adenocarcinoma.
In the present study the hypoxia-inducible pro-apoptotic gene
BNIP3 was analyzed in terms of expression, effect on patient
survival, and chemo-responsiveness in pancreatic cancer cell lines.
PATIENTS AND METHODS: cDNA microarray, QRT-PCR,
laser-capture microdissection and immunohistochemistry analyses
were used to evaluate BNIP3 expression in normal and diseased
pancreatic specimens. Modulation of BNIP3 expression was achieved
using specific siRNA molecules. The effect of chemotherapeutic
agents on pancreatic cancer cells were assessed utilizing MTT assays.
RESULTS: BNIP3 mRNA levels were 3.0-fold and 6.3-fold lower
in chronic pancreatitis and pancreatic cancer compared to the
normal pancreas, respectively. Microdissection analysis confirmed
the reduction of BNIP3 expression from normal ducts to pancreatic
cancer cells. By immunohistochemistry, BNIP3 was predominantly
expressed in the acinar cells of the normal and diseased pancreas.
Interestingly, while BNIP3 was undetectable in the cancer cells of
59% of the cases, 75–100% of PanIN2/3 lesions displayed BNIP3
immunoreactivity. Loss of BNIP3 expression correlated with poorer
survival of patients (8 vs 14 months for BNIP3 negative vs positive
patients). Hypoxia induced BNIP3 expression in 4 of 8 pancreatic
cancer cell lines, while in the remaining 4 it was absent under
normoxic and hypoxic conditions. Down-regulation of BNIP3 re-
sulted in increased resistance to 5-FU and gemcitabine.
CONCLUSION: Loss of BNIP3 expression occurs late in pancreatic
carcinogenesis, contributes to the resistance to chemotherapy, and
correlates with a worsened prognosis in this disease.
3 EXPRESSION OF TISSUE FACTOR IN PANCREATIC
ADENOCARCINOMA IS ASSOCIATED WITH
ACTIVATION OF COAGULATION
Haas SL2, Steiner M1, Hummel F2, Ringel J3, Burstein C1, Horst N4,
Liebe S5, Lo¨hr M2, (1) Department of Clinical Chemistry and
Pathobiochemistry, University of Rostock, Rostock, Germany; (2) II.
Medical Department, University of Heidelberg at Mannheim,
Mannheim, Germany; (3) I. Department of Internal Medicine,
Martin Luther University at Halle-Wittenberg, Halle-Wittenberg,
Germany; (4) Department of Pathology, University of Rostock;
(5) Department of Internal Medicine, University of Rostock,
Rostock, Germany
INTRODUCTION AND AIM: Pancreatic cancer is the tumor
entity with the highest risk for thromboembolic complications.
Tissue factor represents the principal initiator of coagulation.
Aim: To study expression of tissue factor in pancreatic cancer.
PATIENTS AND METHODS: TF expression was studied in
eight human pancreatic tumor cell lines by Northern blot and
indirect immunofluorescence. In addition TF expression was deter-
mined by immunofluorescence in pancreatic tissues of 19 patients
with pancreatic adenocarcinoma (PC), 9 patients with chronic
pancreatitis (CP) and in 20 normal controls (C). Plasma samples
(30 PC patients, 13 CP patients and 20 normal controls) were
investigated for soluble TF levels and coagulation activation markers
(thrombin-antithrombin complex [TAT], prothrombin fragment
1.2). RESULTS: All pancreatic carcinoma cell lines expressed TF.
Expression was not correlated with differentiation of the carcinoma
cell line. In pancreatic tissue, TF expression was negative in all
normal controls and weakly positive in chronic pancreatitis. 17/19
pancreatic carcinomas stained positive for TF. TF (pg/ml), TAT
(ug/L) and PT1.2 (nM) levels in PC patients were significantly
elevated compared to normal controls (288 vs 139, p=0.005, 89 vs
4, p=0.002, 1.2 vs 0.75, p=0.003, respectively). CONCLUSION:
We conclude that in addition to the up-regulated expresssion of TF
on the cell membrane soluble TF might be pivotal for activation of the
coagulation system in pancreatic cancer.
4 PKC 412 – A NOVEL COMPOUND FOR THERAPY OF
PANCREATIC CANCER
Bu¨chler P, Elfitori J, Chirurgische Universita¨tsklinik, Abteilung fu¨r
Allgemein-, Viszeral- und Unfallchirurgie, Heidelberg, Germany
INTRODUCTION AND AIM: Pancreatic cancer is an aggressive
malignancy with a poor prognosis. Currently there is no effective
therapy including surgery since most patients will experience tumor
recurrence shortly thereafter. The increasing awareness of the role
of tumor neo-angiogenesis in growth of solid tumors resulted in
a consensual opinion that abrogated neo-angiogenesis may cause
tumor growth arrest. Angiogenesis is also necessary for local and
systemic tumor progression – both hallmarks of pancreatic cancer.
PKC412 is a novel inhibitor of mutated FLT3, PKC, KDR, c-KIT,
PDGFRa´, and PDGFRaˆ.The aims of this study were to analyse the
therapeutic efficiency of this novel compound in vitro and in vivo
using a novel orthotopic model for experimental pancreatic cancer.
PATIENTS AND METHODS: Five human pancreatic cancer cell
lines AsPc-1 (A1), Capan-1 (C1), HPAF-2 (HP2), PANC-1 (P1)
and MIA PaCa-2 (MP2) were analyzed. RT-PCR was used for
FLT3 mutation in pancreatic cancer cells. Anchorage-dependent
cell growth was quantified with the MTT assay. Soft agar assays
were used to study anchorage-independent growth. Cell cycle
progression was analyzed by flow cytometry. In vivo HP2 and AsPC-
1 cells were used to induce orthotopic tumors in a novel murine
model for pancreatic cancer (n=12 each). Animals received 10 mg/
kg PKC412 i.p. every day for 8 weeks. Immunohistochemistry (anti-
CD31) was used to quantify microvessel density. RESULTS: No
FLT3 mutation could be detected in any of the pancreatic cancer cell
lines. Cell growth was inhibited in all cell lines tested; PKC412
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resulted in a dose- and time-dependent growth suppression. In
flow cytometric analysis a strong G2/M-phase arrest was detectable.
Anchorage-independent growth was also significantly reduced in a
dose-dependent and time-dependent manner. The in vivo correlate
was a significant growth reduction of orthotopic tumors growth
in both cell lines tested. Growth suppression in vivo was mediated
not only by antimitogenic activity but also by suppression of tumor
neo-angiogenesis, as the number of blood vessels in treated animals
was significantly lower. CONCLUSION: PKC412 is a promising
new compound with strong anti-mitogenic and in vivo anti-
angiogenic activity. This dual efficiency will likely be of therapeutic
value for patients with pancreatic cancer.
5 RELEASE OF iC3b FROM APOPTOTIC TUMOR
CELLS INDUCES TOLERANCE BY BINDING TO
IMMATURE DENDRITIC CELLS IN VITRO AND IN VIVO
Schmidt J, Ma¨rten A, Bu¨chler MW, Department of Surgery,
University of Heidelberg, Heidelberg, Germany
INTRODUCTION AND AIM: Chemotherapeutic and immuno-
therapeutic approaches induce apoptosis in tumor cells. Apoptotic
cells are known to activate homologous complement and to be
opsonized with iC3b. As maturation of dendritic cells (DCs) can
be inhibited by binding of iC3b to the complement receptor 3
(CR3, CD11b/CD18) and because immature DCs induce tolerance,
we investigated the induction of tolerance after pulsing DCs with
apoptotic cells in the presence or absence of native serum.
PATIENTS AND METHODS: Apoptosis in pancreatic carcinoma
cells was induced either by heat-stress, chemotherapy or anti-Her2
antibody. Monocyte-derived DCs were pulsed with apoptotic cells
with or without native serum. DCs were analyzed for the maturation
state by flow cytometry and the cytotoxic activity was determined.
Tolerance was prevented by addition of substances such as anti-
CD11b or N-acetyl-D-glucosamine (NADG) which block iC3b
binding to CR3. Furthermore, binding of iC3b from apoptotic cells
to DCs was blocked in a syngeneic pancreatic carcinoma mouse
model. RESULTS: All of the above strategies for apoptosis induction
resulted in iC3b release. Pulsing DCs with apoptotic cells in the
presence of serum prevents maturation of DCs and finally induces
tolerance. This tolerance could be prevented almost completely
by blocking the interaction of iC3b with the CR3 receptor. This
could be shown as well in an immunocompetent mouse model.
CONCLUSION: Chemotherapeutic and immunotherapeutic ap-
proaches induce apoptosis in tumor cells. Release of iC3b from
apoptotic tumor cells prevents full maturation of DCs and immature
DCs induce antigen-specific silencing or tolerance. Blocking of
iC3b-binding could mostly prevent this effect.
6 FXYD3 IS OVER-EXPRESSED IN PANCREATIC
DUCTAL ADENOCARCINOMA AND INFLUENCES
PANCREATIC CANCER CELL GROWTH
Kayed H6, Kleeff J1, Kolb A1, Keleg S1, Felix K1, Giese T2,
Penzel R3, Zentgraf H4, Buechler MW1, Korc M5, Friess H1,
(1) General Surgery, University of Heidelberg; (2) University of
Heidelberg, Institute of Immunology; (3) University of Heidelberg,
Institute of Pathology; (4) Applied Tumor Virology, German Cancer
Research Center, General Surgery, University of Heidelberg,
Heidelberg, Germany; (5) Medicine and Pharmacology and
Toxicology, Dartmouth Medical School, Dartmouth, Dartmouth,
USA; (6) General Surgery - European Pancreas Research Center,
Heidelberg, Germany
INTRODUCTION AND AIM: Deregulation of FXYD3, a trans-
membrane protein acting as a chloride channel or chloride channel
regulator, has been found in some malignancies. In the present
study, the expression and localization of FXYD3 were analyzed in
pancreatic tissues derived from donors and patients suffering from
chronic pancreatitis (CP) or pancreatic ductal adenocarcinoma
(PDAC) as well as in pancreatic cancer cells. PATIENTS AND
METHODS: QRT-PCR, laser-capture microdissection and micro-
array analysis, in situ hybridization and immunohistochemistry
were used to determine the expression and localization of FXYD3.
FXYD3 antisense expressing T3M4 pancreatic cancer cells were
generated and compared with control T3M4 cells in terms of growth
and chemoresistance using anchorage-dependent and -independent
growth assays, and xenotransplantation into nude mice. RESULTS:
FXYD3 mRNA levels were 3.4-fold increased in PDAC tissues
compared to donor specimens (p=0.006), and 3.9-fold increased
in microdissected cancer cells compared to normal ductal cells
(p=0.02). By in situ hybridization and immunohistochemistry,
FXYD3 was localized in the tubular complexes and PanIN lesions
of both CP and PDAC, as well as in pancreatic cancer cells. Down-
regulation of FXYD3 by stable anti-sense transfection significantly
increased the doubling time of T3M4 cells in vitro from 44 h +2 to
55 h+12 (p=0.02), and in vivo from 3.32 days+1.02 to 4.30 days
+0.43 (p=0.058). Anchorage-independent growth and sensitivity
of T3M4 cells to chemotherapeutic drugs and MgCl2 were not
dependent on the level of FXYD3 expression. CONCLUSION:
Over-expression of FXYD3 in pancreatic cancer may contribute to
the proliferation of this malignancy.
7 HEME OXYGENASE-1 (HO-1) MEDIATED IMPAIRED
FUNCTIONALITY OF PERIPHERAL MONONUCLEAR
CELLS IN PANCREATIC CANCER PATIENTS
Dambrauskas Z2, Berberat P1, Gulbinas A2, Mitkus T1, Giese T3,
Giese N1, Meuer S3, Friess H1, Buechler M1, (1) Department of
Surgery, Heidelberg University, Heidelberg, Germany;
(2) Department of Surgery, Kaunas University of Medicine,
Kaunas, Lithuania; (3) Immunology Institute, Heidelberg
University, Heidelberg, Germany
INTRODUCTION AND AIM: Tumor-induced impairment of
immune function may be the reason for fast progression of pan-
creatic cancer. This study determines if the function of peripheral
mononuclear cells (PMNCs) of pancreatic cancer patients shows
changed functionality in comparison to PMNCs of healthy controls.
Furthermore, the role of HO-1 in the function PMNCs of pancreatic
cancer patients is analyzed. PATIENTS AND METHODS: The
expression of HO-1 was analyzed in PMNCs of pancreatic cancer
patients and age-matched healthy controls. The functionality of
PMNCs was assessed by measuring H2O2 and NO production. IL-1
and IL-10 secretion was determined in both groups. Alteration of
PMNC function from healthy controls was analyzed after induction
of HO-1. RESULTS: PMNCs from cancer patients showed marked
overexpression of HO-1 in comparison to healthy controls (p50.05).
HO-1 mRNA was mainly found in CD11- and CD56-positive cells.
HO-1 overexpression correlated with decreased production of H2O2
and NO in cancer patients. After LPS stimulation the PMNCs also
showed decreased IL-1 production and marked increase of IL-10
secretion in comparison to healthy controls. Induction of HO-1 in
PMNCs of healthy controls led to similar alteration of the function
as seen in cancer patients. CONCLUSION: PMNCs of pancreatic
cancer patients show impaired effector functions, including reduced
oxidative burst and anti-inflammatory cytokine secretion pattern.
This phenomenon is at least partly mediated by overexpression of
HO-1 in PMNCs of pancreatic cancer patients. Tumor-mediated
up-regulation of HO-1 in PMNCs may lead to a systemic immuno-
suppressive state in pancreatic cancer patients.
8 THE NEUTROPHIC FACTOR ARTEMIN INCREASES
CANCER CELL INVASION BUT NOT CELL
PROLIFERATION IN PANCREATIC CANCER
Ceyhan GO, Mu¨ller M, Giese N, Mert E, Wente M, Bu¨chler M,
Friess H, Department of General Surgery, University of Heidelberg,
Heidelberg, Germany
INTRODUCTION AND AIM: Invasion of pancreatic nerves by
pancreatic cancer and its extension to the extrapancreatic nerve
plexus are still poorly understood events. It leads to retropancreatic
tumor extension, precludes curative resection, promotes local
recurrence and has a negative impact on survival. To understand
the process of neural invasion, Artemin – a neurotrophic factor –
and its receptors (RET-GFRa3) were studied in pancreatic cancer.
PATIENTS AND METHODS: Tissues from 31 patients under-
going resection for pancreatic cancer, 10 liver metastases and 19
healthy organ donors were investigated by Western blot analysis,
immunohistochemistry and QRT-PCR. Artemin was also deter-
mined in the pancreatic cancer cell lines Colo-357, Mia-PaCa-2,
BxPc-3, SU-8686, Panc-1, Capan-1, Aspc-1 and T3M4. The
influence of Artemin on proliferation was analyzed via a MTT test
and its effects on invasion were investigated by using Biocoat-
Matrigel invasion chambers. RESULTS: Artemin mRNA expression
was increased in pancreatic cancer compared to normal pancreas.
The highest and lowest levels of Artemin mRNA in pancreatic cancer
cell lines were found in T3M4 and Panc-1, respectively. Western blot
analysis revealed strong Artemin and RET-GFRa3 levels in
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pancreatic cancer, compared to normal pancreas. By immuno-
histochemistry, pancreatic cancer and liver metastasis samples
exhibited strong Artemin and RET-GFRa3 immunoreactivity
in arteries, nerves, tubular complexes and pancreatic cancer cells.
In normal pancreas, however, Artemin immunostaining was only
present faintly in arteries. Artemin caused no striking effect on cell
proliferation in none of the pancreatic cancer cell lines. However,
Artemin increased the invasion capacity of pancreatic cancer cell
lines up to three to five times. CONCLUSION: Artemin promotes
pancreatic cancer cell invasion, but not proliferation. Its presence
in metastatic cancer cells suggests that Artemin might also have an
influence on the formation of metastases.
9 OSTEOPONTIN MODIFIES THE INVASIVENESS OF
PANCREATIC CANCER CELLS: POTENTIAL THERAPEUTIC
AND DIAGNOSTIC MARKER
Kolb A, Kleeff J, Guweidhi A, Bu¨chler MW, Friess H, Department
of General Surgery, University of Heidelberg, Heidelberg, Germany
INTRODUCTION AND AIM: Osteopontin (OPN) is a secretory
protein with a variety of functions, in for example, cell adhesion and
migration, inflammatory reaction and apoptosis. OPN can increase
tumor growth, invasiveness and metastases, and it has also been
suggested to serve as a biological marker in certain tumors. Aim:
The functional role of OPN in human pancreatic cancer and its
potential use as a new disease marker were analyzed. PATIENTS
AND METHODS: OPN expression in normal pancreas and
pancreatic cancer were examined by RT-QPCR and immuno-
histochemistry. Serum levels of donors and patients with pancreatic
diseases were analyzed by ELISA. Growth experiments, RT-QPCR
and ELISA were used to analyze cultures of pancreatic cancer cells.
Invasion experiments were performed with siRNA transfected
pancreatic cancer cells and specific OPN receptor blockade.
RESULTS: In RT-QPCR, there was a 2.5-fold increase of OPN
mRNA in pancreatic cancers compared to normal pancreatic tissues.
Immunohistochemical analysis demonstrated OPN staining in 60%
of the primary pancreatic tumors and in 72% of the metastases.
ELISA analysis of serum samples showed a 2.1-fold increase in OPN
serum levels in tumor patients. Recombinant human OPN signifi-
cantly increased the invasiveness of pancreatic cancer cells, without
having any impact on cell proliferation. In addition, down-regulation
of OPN by specific siRNA molecules decreased pancreatic cancer
cell invasion. CONCLUSION: OPN serum levels in pancreatic
cancer patients derive most probably from the increased OPN
production by the tumor cells, thus suggesting a possible role of
OPN as a prognostic or follow-up marker. Our results also suggest
that blockade of OPN might be useful as a therapeutic approach to
inhibit invasion and metastasis of pancreatic cancer cells.
10 IN VITRO ANALYSIS OF THE ROLE OF
INTERFERON-ALPHA IN COMBINED
CHEMORADIOIMMUNOTHERAPY IN THE ADJUVANT
TREATMENT OF PANCREATIC ADENOCARCINOMA
(CapRI)
Patrut E, Ma¨rten A, Schmidt J, Knaebel HP, Bu¨chler M,
Department of Surgery, University of Heidelberg, Heidelberg,
Germany
INTRODUCTION AND AIM: Adjuvant treatment of pancreatic
adenocarcinoma has failed so far to produce long-lasting benefits.
Results from a phase II trial, where chemoradiotherapy was com-
bined with IFN-alpha (CapRI scheme), are very encouraging. We
hypothesize that IFN-alpha is the agent that turns a slightly effective
treatment (radiochemotherapy) into a potent therapy. PATIENTS
AND METHODS: Eight pancreatic carcinoma cell lines were
treated with the single agents and combinations of these. The role
of IFN-alpha regarding a) direct inhibitory effects; b) radio- and
chemo-sensitizing effects; c) anti-angiogenic properties and d)
enhancement of immunogenicity was investigated. RESULTS: Our
results show that IFN-alpha has direct inhibitory properties and some
synergistic influence as determined by Annexin V/PI stain and cell
count. IFN-alpha is also able to prevent the increase in proliferation
rate and VEGF secretion of CDDP resistant cells. Taking the
results from immunogenicity experiments together, we found cells
that can be influenced by IFN-alpha but that are less susceptible
against T cells. Furthermore, high expression of MHC molecules,
CD118, EGF-R and Fas was predictive of a good response.
CONCLUSION: In conclusion, IFN-alpha has direct cytotoxic
effects, acts as a radiosensitizer and circumvents tumor cell regrowth
after CDDP treatment. These mechanisms may be responsible for
the good clinical outcome of CapRI.
11 IDENTIFICATION OF DIFFERENTIALLY
EXPRESSED GENES IN THE STROMAL TISSUE OF
PANCREATIC DUCTAL ADENOCARCINOMA AND
CHRONIC PANCREATITIS
Gru¨tzmann R3, Lu¨ttges J1, Klo¨ppel G1, Ammerpohl O2, Kalthoff H2,
Saeger HD3, (1) Pathology, University Kiel; (2) Surgery, University
Kiel, Kiel, Germany; (3) Department of Visceral-, Thoracic and
Vascular Surgery, University Hospital Dresden, Dresden, Germany
INTRODUCTION AND AIM: Prognosis for patients with
pancreatic ductal adenocarcinoma (PDAC) remains poor. Despite
increasing knowledge about the molecular basis of PDAC no specific
marker for early diagnosis nor a target protein for a new therapeutic
approach have been identified so far. Moreover, PDACs display
large desmoplasia, indicating that the activation of tumor surround-
ing stroma plays a key role during PDAC development. We were
therefore interested in the analysis of differential gene expression
between tumor surrounding stroma and the stroma compartment
of chronic pancreatitis. PATIENTS AND METHODS: We micro-
dissected the stromal tissue compartment of six pancreatic cancer
and six chronic pancreatitis tissues. Moreover 20 microdissected
samples of PDAC and 15 of normal ductal cells have been used.
Manual microdissection has been applied to get pure cell compart-
ments. The tissues were obtained during surgery and freshly frozen.
The mRNA was extracted, amplified using repetitive in vitro
transcription and hybridized to the Affymetrix U133 A+B Gene-
Chip set. The data obtained from the microarray were normalized
and signal intensities were calculated using dCHIP. Differentially
expressed genes were identified using SAM (cut-off: fold change43,
q-value 55%). RESULTS: We identified 195 differentially expres-
sed genes of which 39 were over-expressed and 157 were under-
expressed in pancreatic cancer stroma. Hierarchical clustering using
the 195 genes and the gene expression profiles of microdissected
pancreatic tumor epithelia identified a subset of pancreatic cancer
epithelia displaying gene expression similar to the cancer stroma.
Annotation of the 195 genes resulted in the identification of soluble
factors from the Wnt and the Notch signalling pathways over-
expressed in the stroma from cancer tissue. Several genes are now
subjected to further validation. CONCLUSION: In conclusion, gene
expression analysis of the stromal compartment could identify new
markers and therapeutic targets for the tumor-associated stroma
of pancreatic cancer.
12 MOESIN: EXPRESSION AND FUNCTIONAL
STUDIES IN PANCREATIC CANCER
Abiatari I2, Kleeff J1, Giese NA1, Buchler MW1, Friess H1,
(1) Department of General Surgery, University of Heidelberg;
(2) University of Heidelberg, Department of General Surgery,
European Pancreas Research Center, Heidelberg, Germany
INTRODUCTION AND AIM: Moesin (membrane organizing
extension spike protein) is a member of the ERM (Ezrin, Radixin,
Moesin) protein subfamily, which has been proposed to link integral
proteins to the actin component of the cytoskeleton. Having struc-
tural functions, it has been implicated in the regulation of signaling
events in epithelial cells. Recent studies have shown a correlation
between the deregulation of Moesin expression and the aggressive-
ness of tumor cells in different types of cancer. This study aimed to
investigate the expression and localization of Moesin in pancreatic
cancer tissues and pancreatic cancer cell lines, and to evaluate its
importance in adhesion and invasion of pancreatic cancer cells.
PATIENTS AND METHODS: Quantitative RT-PCR was used
to determine Moesin mRNA levels. Immunohistochemistry and
immunofluorescence were carried out to localize Moesin in pan-
creatic tissues and in pancreatic cancer cell lines. Adhesion and
invasion assays were performed in control and following Moesin-
specific siRNA transfection. Immunoblot analysis was used to
monitor protein levels. RESULTS: QRT-PCR revealed a 2.4-fold
increase of Moesin mRNA in pancreatic cancer tissue in comparison
to normal pancreatic tissues. Moesin was expressed in the proximity
of the plasma membrane in pancreatic cancer cell lines. A significant
down-regulation of Moesin was observed 72 h after siRNA trans-
fection in pancreatic cancer cell lines, which was accompanied by
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an increase of the invasion capacity and a reduction of adhesion
in pancreatic cancer cell lines. CONCLUSION: Moesin displays a
membranous pattern of expression in pancreatic cancer cell lines and
suppression of Moesin expression decreases adhesion and increases
invasion in pancreatic cancer cells.
13 INCREASED EXPRESSION OF TUMOR-ASSOCIATED
ANTIGEN RCAS1 ALONG WITH PANIN PROGRESSION
TO INVASIVE PANCREATIC ADENOCARCINOMA
Ito D, Fujimoto K, Kami K, Doi R , Surgery and Surgical
Basic Science, Kyoto University, Kyoto, Japan
INTRODUCTION AND AIM: RCAS1 (receptor-binding cancer
antigen expressed on SiSo cells) has been reported as a tumor-
associated antigen, which contributes to immunologic tolerance of
cancer through induction of apoptosis of T, B or NK cells. Over-
expression of this molecule has been reported in many types of
cancers. We hypothesized that RCAS1 might also play a certain
role in pancreatic cancer development. To assess this hypothesis,
we immunohistochemically examined the expression of RCAS1 in
invasive pancreatic ductal adenocarcinomas (IPDAs) and pancreatic
intraepithelial neoplasia (PanINs), which are now proposed as
precancerous lesions of pancreatic ducts. PATIENTS AND
METHODS: Immunohistochemical analysis was performed in 24
IPDAs, 1 IPDA with PanINs and 3 carcinoma in situ with PanINs
using anti-RCAS1 antibody. Correlation between the expression of
RCAS1 and clinocopathological features was evaluated. RESULTS:
RCAS1 was highly expressed in strong cytosolic and membranous
staining of RCAS1 was seen in 19 cases of 25 IPDAs (76%), whereas
no staining was detected in normal pancreatic epithelia. In PanINs,
the proportion of the specimens regarded as positive was as follows:
0/2 lesions in 0%, 1/4 lesions in 25%, 1/2 lesions in 50% and 4/4
lesions in 100%, respectively. There was no statistical correlation
with survival and clinocopathological features in these series of
immunohistochemstry. CONCLUSION: RCAS1 was highly ex-
pressed in IPDAs and the proportion of the specimens regarded as
positive increased along with PanIN progression. These results
suggest that RCAS1 might play a certain role in pancreatic cancer
development.
14 HISTONE DEACETYLASE (HDAC) INHIBITORS
ENHANCE THE APOPTOTIC EFFECTS AND THE
GROWTH REDUCTION ACTIVITY OF GEMCITABINE
IN PANCREATIC CARCINOMA CELL LINES
Bonora A3, Beghelli S1, Donadelli M2, Cavallini A3, Bassi C3,
Palmieri M2, Pederzoli P3, (1) Department of Pathology, University
of Verona; (2) Department of Neurological Sciences, Biochemistry
Unit, University of Verona; (3) Department of Surgical Sciences,
University of Verona, Verona, Italy
INTRODUCTION AND AIM: Gemcitabine, though considered
the most active agent in pancreatic cancer chemotherapy, does not
exceed a 20% rate in clinical response, this resistance being probably
related to the alteration of apoptosis-regulating genes, mainly
p53. HDAC inhibitors promote hyperacetylation and highly induce
apoptosis in both p53-positive and -negative tumour cells. Therefore
we evaluated the effects in nude mice of the association of a
HDAC inhibitor, like TSA, and gemcitabine. PATIENTS AND
METHODS: A p53-defective pancreatic cancer cell line (T3M4)
was subcutaneously implanted in four groups of five nude mice. Each
group was then randomly treated with a twice-weekly administration
of either DMSO (as control), or TSA (0.25 mg/kg), or gemcitabine
(2.5 mg/kg), or TSA plus gemcitabine during a 4-week period.
Tumour growth and body weight were monitored and the animals
were sacrificed at the end of the scheduled treatment. RESULTS:
Neither toxicity nor mortality was observed in any group. The
combined treatment significantly enhanced cell apoptosis in
tumour section compared with the control group in a 1.43 : 1 rate
(p50.02). Histone acetylation levels showed a three-fold increase
in TSA treated versus untreated groups. We reported a tumour
weight significant reduction (p50.01) in the combined treatment
group (2.98+1.5) if compared both with control (5.74+1.7) and
single treatment groups (6.34+1 and 5.98+1.7, respectively).
CONCLUSION: The association of TSA and gemcitabine seems
able to reduce pancreatic cancer tumour growth in vivo. These data
need to be confirmed in larger studies to provide a rational basis
for further clinical trials.
15 STANNIOCALCIN-1 IS UP-REGULATED IN
PANCREATIC CANCER
Salabat MR1, Adrian T2, Ding XZ1, Wagner GF1, DiMattia GE1,
Talamonti MS1, Bell RH1, (1) Department of Surgery and Robert H.
Lurie Comprehensive Cancer Center, Feinberg School of Medicine,
Northwestern University, Chicago, IL, Department of Physiology
and the London Regional Cancer Center, University of Western
Ontario, USA; (2) Northwestern University Feinberg School of
Medicine, Surgical Research Departments of Surgery and Pathology,
Chicago, USA
INTRODUCTION AND AIM: Stanniocalcin-1 (STC-1) is a
polypeptide hormone originally found in bony fish, involved in
calcium and phosphate homeostasis. STC-1 is widely expressed
in different tissues in mammals, including the pancreas. STC-1 has
diverse roles in mammals, including metabolic effects on target
cell mitochondria. Transgenic mice overexpressing STC1 exhibit
metabolic wasting, hyperphagia and a dwarf phenotype. STC-1 may
be a marker for breast cancer and to detect minimal residual disease
in acute myelogenous leukemia. PATIENTS AND METHODS:
The present study investigated the expression of STC-1 in pancreatic
cancer, using expression microarray, real-time RT-PCR, Western
blotting and immunocytochemistry. RESULTS: Microarray
analysis of CD18 pancreatic cancer cells, revealed STC-1 among up-
regulated genes in response to the phorbol ester, TPA. Time- and
concentration-dependent increased expression of STC-1 was con-
firmed by real-time RT-PCR. Western blotting showed that STC-1
protein was markedly increased in media, but not lysates of TPA-
treated CD18 cells. TPA also increased STC-1 promoter activity.
Immunocytochemistry showed intense STC-1 staining in pancreatic
cancer tissue. Investigation of the putative receptor using an STC-1/
alkaline phosphatase fusion protein, showed increased ligand
binding in cancer tissues. CONCLUSION: STC-1 and its putative
receptor are up-regulated in pancreatic cancer tissue and cells. TPA
induces time- and concentration-dependent expression of STC-1
mRNA and protein in pancreatic cancer cells. Further investigation
will reveal the role of stanniocalcin-1 in pancreatic cancer and
whether this polypeptide may be valuable as a marker or therapeutic
target in this disease.
16 p-21waf1 EXPRESSION IS UP-REGULATED
THROUGH A P38 KINASE-DEPENDENT MECHANISM
IN ASSOCIATION WITH FRONDANOL1-A5P-INDUCED
CELL CYCLE ARREST AND APOPTOSIS IN PANCREATIC
CANCER
Roginsky AB1, Adrian T2, Singh B1, Ujiki MB1, Ding XZ1, Collin
P1, Woodward C1, Talamonti MS1, Bell RH1, (1) Department of
Surgery and Robert H. Lurie Comprehensive Cancer Center,
Feinberg School of Medicine, Northwestern University, Chicago, IL
and Coastside Research, Stonington, ME, USA, (2) Northwestern
University Feinberg School of Medicine, Surgical Research
Departments of Surgery and Pathology, Chicago, USA
INTRODUCTION AND AIM: Pancreatic cancer has a grave
prognosis due to late diagnosis and lack of effective therapy.
Frondanol1 A5, produced from an edible sea cucumber, inhibits
growth of pancreatic cancer cells. In the present study, we examined
the effects of a polar sub-fraction, Frondanol1-A5P on cell cycle
and apoptosis. PATIENTS AND METHODS: Cells were cul-
tured in serum-free conditions 24 h prior to treatment. Cells were
stained with propidium iodide for cell cycle analysis. Cell cycle and
apoptosis-related proteins were evaluated by Western blotting.
mRNA was quantified by real-time RT-PCR. RESULTS: G2/M
arrest was seen by flow cytometry in both AsPC-1 and S2-O13 cells
after treatment with 15.5 mg/ml for 24 h. Treatment decreased
expression of cyclins A, B, D and E. Phosphorylation of p-38 and
SAPK/JNK were seen at 5 min. Treatment also increased p21waf1
protein and mRNA (8-32 fold at 3 h). Pre-treatment of the cells
with the phospho-p38 inhibitor, SB203580, reduced the amount
of p21waf1 mRNA. Caspase-3 activation provided evidence of
apoptosis. CONCLUSION: Apoptosis induced by Frondanol1-
A5P is associated with a marked increase in expression of the
p-21waf1 mRNA and protein. It is likely that p-21waf1 mediates
the apoptotic and cell cycle effects of the sea cucumber-derived
agent. The increased expression of this pro-apoptotic and cell cycle
arrest protein is mediated by a p38 kinase-dependent mechanism
and is likely stabilized by phospho-JNK. Since Frondanol1-A5P
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comes from an edible, nontoxic source, it may be valuable for therapy
or prevention of pancreatic cancer.
17 EXPRESSION OF STEROID HORMONE RECEPTORS
AND OTHER BREAST CANCER-ASSOCIATED GROWTH
FACTORS IN PANCREATIC ADENOCARCINOMA
Spinelli A1, Raab C1, Heinz T2, Benckert C1, Langrehr JM1,
Rudolph B3, Neuhaus P1, Jonas S1, (1) Allgemein-, Visceral- und
Transplantationschirurgie, Charite´ Campus Virchow Klinikum;
(2) Universitaetsfrauenklinik, Hormonlabor, Charite´ Campus
Virchow-Klinikum; (3) Institut f. Pathologie, Charite´ Campus Mitte,
Berlin, Germany
INTRODUCTION AND AIM: The role of hormonal regulation
in pancreatic adenocarcinoma growth is still unclear. Our aim is
to dose the expression of progesterone receptors (PRs), estrogens
receptors (ERs), cathepsin D, pS2, p53 and c-erbB2 in specimens
of pancreas adenocarcinoma and to correlate these data with
the clinical parameters and outcome of patients. PATIENTS AND
METHODS: Hormone receptors and growth factors were quanti-
tatively determined by enzymatic immunoassay in specimens
from 56 pancreas carcinomas and from 11 chronic pancreatitis.
RESULTS: Nine pancreatic carcinomas (16%) were ER-positive
(cut-off: 1.5 fmol/mg), 16 pancreatic carcinomas (28.5%) PR-
positive (cut-off: 1.7 fmol/mg). PR and ER were common in poorly
differentiated carcinomas (G3) (p=0.15 and 0.12, respectively).
There was a trend towards an increased rate of detection of PRs
in advanced tumor stages (p=0.07). Two specimens obtained
from patients suffering from pancreatitis expressed hormonal
receptors (1 ERs, 1 PRs). A trend towards an accumulation of PRs
in pancreatic carcinomas compared with pancreatitis was identified
(p=0.17). pS2 was found to be expressed in 10.7% of the carcinomas
(all of them hormone receptor positive) and in none of the
pancreatitic specimens. The mediane cathepsin D concentration
in cancers was significantly higher than in the control group (p=0.02;
Mann-Whitney test). Additionally, 13 (23%) carcinomas were
p53-positive and 45 (80%) carcinomas were c-erbB2-positive. None
of the considered factors, except radical resection, revealed a
prognostic influence on the survival (univariate analysis, log-rank-
test). CONCLUSION: The significantly different concentration of
cathepsin D in pancreatitis and tumor could suggest a role of this
protein as a parameter for tumor progression.
18 NEUROMEDIN U IS A SPECIFIC MARKER
FOR PANCREATIC DUCTAL ADENOCARCINOMA
AND ENHANCES INVASIVENESS
Ketterer KM, Frank D, Giese N, Bu¨chler MW, Friess H,
Department of General Surgery, University of Heidelberg,
Heidelberg, Germany
INTRODUCTION AND AIM: Microarray analysis revealed a
specific overexpression of the neuropeptide Neuromedin U (NmU)
in pancreatic cancer samples compared with chronic pancreatitis and
normal pancreas. Therefore the potential of NmU as a diagnostic
marker and the putative role of NmU in pancreatic cancer carcino-
genesis was further investigated. PATIENTS AND METHODS:
Expression of NmU and its receptors NmUR1 and 2 was analysed
in pancreatic cancer cell lines and human pancreatic specimens by
QT-PCR, immunohistochemistry, Western blot and by ELISA of
serum samples. NmU-stimulated cells were analysed by cDNA
microarrays. In addition the role of NmU in cell proliferation and
migration was tested. RESULTS: A significant overexpression of
NmU (p=0.0022) and NmUR2 (p=0.0016) mRNA in cancer and
metastatic tissues was found by QT-PCR. According to IHC, protein
expression was localized predominantly in cancer ducts but also
hypertrophic nerves and tubular complexes in primary tumours
and in cancer cells of metastasic lesions. Serum levels of NmU did
not differ significantly between the various groups; however, indi-
vidual NmU-serum levels dropped considerably after tumour
resection, indicating NmU as a possible serum marker for tumour
recurrence. NmU treatment induced c-met up-regulation and
accordingly NmU treatment promoted rHGF-induced scattering of
tumour cells. CONCLUSION: We report that NmU and its receptor
NmUR2 are over-expressed in pancreatic cancer on mRNA and on
protein level. Besides its role as a clinical marker, we suggest an
involvement of NmU in the HGF-Met paracrine loop regulating
cell migration and thus invasive tumour growth and dissemination
of cancer cells in PDAC.
19 EXPRESSION OF CYTOKERATIN-20: AN
INDICATOR OF POOR OUTCOME IN RESECTED
PANCREATIC CANCER
Schmitz-Winnenthal FH1, Z’graggen K3, Berger S1, Volk C1,
Kleeff J1, Friess H1, Weitz J1, Helmke BC2, Hinz U1, Bu¨chler MW1,
(1) Department of Surgery, University of Heidelberg;
(2) Department of Pathology, University of Heidelberg,
Heidelberg, Germany; (3) Klinik Beau-Site Hirslanden,
Department of Surgery, Bern, Switzerland
INTRODUCTION AND AIM: Even after radical surgery (R0)
*80% of pancreatic cancer patients will die of the disease within
5 years. At present no reliable indicators of prognosis after radical
resection are available. The expression panel of cytokeratins (CK) is
closely linked with specific programs of cell differentiation. The aim
of the study was to investigate the expression of CK-20 in pancreatic
cancer tissue and to correlate CK-20 expression with tumor recur-
rence and survival in radically resected pancreatic cancer patients.
PATIENTS AND METHODS: Tissue samples of 63 patients with
pancreatic cancer were obtained intraoperatively and subjected to
CK-20 RT-PCR. 34/63 patients underwent potentially curative
resection and were followed for disease recurrence and survival.
From the 34 R0 patients, 26 (76.5%) tumors were CK-20-positive
and 8 (23.5%) tumors were CK-20-negative. The mean follow-up
period for the entire group was 12.7 months (range 4–24.3), follow-
up in censored patients was 14.7 months (range 6.3–24.3).
RESULTS: Considering the R0 resected group, none of the patients
with CK-20-negative tumors, but 12 of 26 (46%) patients with
CK-20-positive tumors (p=0.02) died of recurrent disease. The
median survival time of patients with CK-20-positive tumors
was 9 months (4–11.6), median survival was not reached in R0
resected patients with CK-20-negative tumors (follow-up period of
16.7 months). The survival advantage observed in patients with
CK-20-negative tumors could not be attributed to intergroup
variations in tumor stage or tumor grade. CONCLUSION: The data
suggest that in patients undergoing radical resection of pancreatic
cancer, CK-20 expression is associated with increased aggressiveness
and a poorer survival. Accordingly, negativity for CK-20 defines a
subgroup of patients exhibiting a more favorable disease outcome.
The expression of CK-20 in resected pancreatic cancer may be
of interest as a prognostic test.
20 IMMUNOMODULATORY IMPACT OF
INTERFERON-ALPHA IN COMBINATION WITH
CHEMORADIATION OF PANCREATIC
ADENOCARCINOMA (CapRI)
Ma J, Schmidt J, Ma¨rten A, Patrut E, Knaebel HP, Bu¨chler M,
Department of Surgery, University of Heidelberg, Heidelberg,
Germany
INTRODUCTION AND AIM: Adjuvant treatment of pancreatic
adenocarcinoma has so far shown only moderate results. Data from
a phase II trial, where chemoradiotherapy was combined with
IFN-alpha (CapRI scheme), are very encouraging. We hypothesize
that IFN-alpha is the agent that improves radiochemotherapy
significantly. Here, we focused on the immunomodulatory effect
of IFN-alpha. PATIENTS AND METHODS: Eight pancreatic
carcinoma cell lines were treated with the single agents 5-FU,
CDDP, IFN-alpha, irradiation and/or combinations of these. The
immunomodulatory capacity of IFN-alpha was investigated in
cytotoxicity assays against these cell lines. Immune cells were
preincubated with 1000 U/ml IFN-alpha over 24 h. RESULTS:
Our results show an increase in cytotoxic activity of peripheral
blood mononuclear cells after IFN-alpha treatment from 12.5% to
34.3% (p50.05). This cytotoxicity was NK cell-mediated as it was
shown after depletion of T cells (T cells 4% lysis, NK cells 42.7%
lysis). The T cell depleted fraction was to 60% CD16+, CD56+
and expressed to 50% the IFN-a receptors CD118 and CD21.
Monocytes were not involved either in killing or in activation
(IFN-alpha stimulation in the absence of monocytes 29.4% killing
vs 34.3% after stimulation of all mononuclear cells). Pretreatment
of tumor cells with chemoradiation showed a significant increase
in susceptibility of tumor cells against NK cells after treatment with
5-FU and combinations (5-FU alone 66.9% lysis, CapRI scheme
69.1%, untreated tumor cells 34.3%). CONCLUSION: IFN-alpha
activates NK cells against pancreatic carcinoma cells and 5-FU
treatment makes tumor cells more susceptible. These mechanisms
may be responsible for the good clinical outcome of CapRI.
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21 TREATMENT OF PANCREATIC CANCER WITH
ANTISENSE THERAPY SPECIFIC TO MUTATED K-RAS
GENE IN VITRO AND IN VIVO IN SYRIAN GOLDEN
HAMSTERS – IS IT SUITABLE?
Morioka CY1, Matheus AS1, Saito S2, Machado MCC1, Cunha
JEM1, Yamago GI3, Watanabe A2, (1) Department of Surgery,
University of Sa˜o Paulo, Brazil; (2) 3rd Department of Internal
Medicine, Toyama Medical and Pharmaceutical University,
Toyama, Japan; (3) Department of Cell Biology, Okayama
University Medical School, Okayama, Japan
INTRODUCTION AND AIM: Pancreas cancer prognosis is still
reserved constituting a medical challenge. About 490% of this
type of cancer carry the K-ras point mutation, which may play an
important role in tumoral progression. Antisense oligonucleotides
(ASO) targeting this gene may be a therapeutic choice. Thus, our
aim was to elucidate the effectiveness of this gene therapy in a
hamster experimental pancreatic cancer model. PATIENTS AND
METHODS: HaP-T1, a cell culture derived from nitrosamine-
induced hamster pancreatic cancer was used. MTT, MTT-agarose,
Western blotting, and in vitro chemoinvasion assays were performed
using ASO specific to K-ras gene. In exponential phase of growth, a
tissue derived from subcutaneously implanted cancer cells was
implanted into the pancreas. Animals were divided in 3 groups: 1.
Positive control (PC), 2. Sense-treated hamsters (STH), and 3.
Antisense-treated hamsters (ATH). Oligonucleotides were admin-
istered for 2 weeks. Follow-up was done by evaluation of the tumor
growth by palpation, ‘general state’, weight, and side effects. Five
animals of each group were sacrificed at days 10, 17, 24, 31, 38, to
study the local response and metastatic sites. Five animals of each
group were left to study the survival time. Necropsy was performed
and specimens were studied histopathologically. RESULTS: ASO
inhibited the tumoral growth by suppression of K-ras p21 protein
synthesis. It could also inhibit the invasiveness. All tumors were
palpable. Positive controls, STH, and ATH survived on average
72.7, 73.8, and 79.6 days, respectively. Side effects were observed
in both oligonucleotide-injected groups. Tumor sizes were on aver-
age smaller in the ATH group throughout the study. Spontaneous
lymph node metastases were found from 31 days in the ATH group,
while PC and STH groups showed metastases and direct invasion
to adjacent organs from 17 days. After death, metastatic sites were
similar in the 3 groups. Liver metastasis has a higher incidence in PC;
moreover, only the PC group showed ascites. CONCLUSION:
Antisense oligonucleotides inhibited tumor growth and invasiveness,
and improved liver metastatic rate and ascites. Therefore, it may be
a good approach in the management of pancreatic cancer. Moreover,
it may contribute as neoadjuvant and/or adjuvant therapy.
22 METHYLENE BLUE AND THE REDUCTION OF
PERITONEAL CARCINOMATOSIS IN HAMSTER
EXPERIMENTAL PANCREATIC CANCER MODEL – IS IT
A PROMISING THERAPY?
Matheus AS1, Morioka CY1, Machado MCC1, Saito S2,
Jukemura J1, Cunha JEM1, Watanabe A3, (1) Department of
Surgery, University of Sa˜o Paulo, Brazil; (2) 3rd Department of
Internal Medicine, Toyama Medical and Pharmaceutical University;
(3) 3rd Department of Internal Medicine, University of Sa˜o Paulo,
Brazil
INTRODUCTION AND AIM: Methylene blue, hematoporphyrin
derivative Halle and chlorophyllin produce a marked reduction
of tumor weight. In addition, it is known to inhibit the generation of
oxygen radicals. This dye has been tried experimentally to prevent
adhesion formation. However, it has never been reported in the
prevention of tumoral adhesion. The aim of the present study was
to elucidate the effectiveness of methylene blue to prevent peritoneal
tumoral implantation in a hamster experimental pancreatic cancer
model. PATIENTS AND METHODS: Tumor cell suspensions
were injected intraperitoneally. Animals were divided in two groups:
A. only injection (positive control, n=10) and B. injection and
administration of methylene blue after the injection (n=10). The
animals were observed and weighed until 14 days, when they were
sacrificed. After necropsy, ascites volume was quantified and
numbers of implantations were measured RESULTS: Hamsters of
Group A were shown to be heavier throughout the experiments. After
necropsy, Group A had an average 7.4 ml of ascites and generalized
peritoneal carcinomatosis including diaphragm and Group B showed
an average 2.6 ml of ascites and an average 9.4 implants located
mainly in the pelvic region. CONCLUSION: The present study
showed that methylene blue decreased the number of pancreatic
cancer implants and the volume of ascites. This substance may be
used as an adjuvant therapy to decrease or even prevent the adhesion
of possible metastatic cells in the peritoneal wall.
23 PANCREATIC CANCER CELLS EXPRESS A UNIQUE
NEUROGENIC FACTOR, BETA-TUBULIN
Standop J2, Yalniz M1, Saruc M1, Pour PM1, (1) Eppley Research
Institute, UNMC, University of Nebraska Medical Center
(UNMC), Omaha, USA; (2) University of Bonn, Department
of Surgery, Bonn, Germany
INTRODUCTION AND AIM: It has been known that islets of
Langerhans share similarities in the expression of neuroendocrine
markers, including N-CAM, NSE, synaptophysin and chromogranin
A. These markers are also expressed in some pancreatic carcinomas
of ductal phenotype, suggestive of a neuroendocrine differentiation.
One of the most specialized tubulins specific for neurons is class III
beta-tubulin, which is essential throughout neuronal differentiation.
Because we believe that pancreatic ductal cell carcinomas derive
from transdifferentiated islet cells, we investigated the expression of
beta-tubulin in pancreatic tissue. PATIENTS AND METHODS:
Three normal pancreata (NP) and 15 ductal type adenocarcinomata
(PC) with different differentiation grade as well as cultured human
islet cells were examined by immunohistochemistry using a mono-
clonal and a polyclonal antibody against (class III) beta-tubulin.
RESULTS: In the normal pancreatic tissue, the immunoreactivity
of the polyclonal antibody was restricted to the islet cells, whereas
14 of 15 PC showed the expression of beta-tubulin. Within the
islets, alpha-cells showed the strongest immunoreactivity. The
reactivity of the monoclonal antibody with cancer cells, however,
differed greatly. Only in three cases all pancreatic cancer cells were
stained, three cases showed no staining and in the remaining cases
the immunoreactivity varied between 20% and 70%. The immu-
noreactivity of islets within and outside of cancer were diminished
or lost. Cultured human islet cells were immunoreactive with both
antibodies. CONCLUSION: The results, thus, lend further
support for the common origin of pancreatic ductal carcinomas and
pancreatic islets from neuroendocrine cells.
24 PRIMARY AND METASTASTIC PANCREATIC
ACINAR CELL CARCINOMA: A MOLECULAR ANALYSIS
Bergmann F1, Aulmann S1, Esposito I1, Kleeff J2, Friess H2,
Schirmacher P1, (1) Institute of Pathology; (2) Department of
General Surgery, University of Heidelberg, Heidelberg, Germany
INTRODUCTION AND AIM: Pancreatic acinar cell carcinomas
(PAC) are associated with a poor prognosis. At the time of diagnosis,
approximately half of the patients display metastatic spread, usually
affecting regional lymph nodes and the liver. To date, cytogenetic
and molecular analyses have been limited to a few cases of primary
PAC; however, no data have been obtained for their metastases.
Therefore, the present study was designed to detect possible differ-
ences between primary and metastatic PAC. PATIENTS AND
METHODS: Three primary PAC, one corresponding regional
lymph node metastasis and two corresponding hepatic metastases
were characterised by means of comparative genomic hybridisation,
fluorescence in situ hybridisation, and immunohistochemistry.
RESULTS: Chromosomal imbalances were detected in all tumors,
most consistently affecting gains of 1q, 8q, 12, 17, 20q and 22q, as
well as losses of 1p, 4q, 11q and 18q. In general, similar chromosomal
imbalances were seen in primary and metastatic PAC. However,
some changes, including gains of 3p, 8q, and 17q, were more
frequent or limited to metastatic PAC. Low level amplifications of
c-MYC (8q24) were detected in the primary tumor and in one
hepatic metastasis of one patient. Neither primary nor metastatic
PAC revealed expression of Her2/Neu (17q21). CONCLUSION:
PAC display a consistent chromosomal profile, which shows a
large overlap between primary and metastatic PAC. Chromosomal
imbalances, more frequently or exclusively occurring in metastatic
PAC, indicate chromosomal loci possibly harboring candidate genes
that are involved in tumor progression and spread.
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25 REDUCED EXPRESSION OF TUBERIN
IS ASSOCIATED WITH PANCREATIC CANCER
DEVELOPMENT
Kataoka K, Ito D, Fujimoto K, Doi R, Surgery and Surgical
Basic Science, Kyoto University, Kyoto, Japan
INTRODUCTION AND AIM: Tuberous sclerosis complex (TSC)
is an autosomal dominant disorder caused by mutation in either
the TSC1 or TSC2 tumor suppressor genes. Recent studies have
revealed that TSC1/TSC2 proteins (hamartin/tuberin, respectively)
function downstream of Akt and upstream of mTOR, and are one
of the regulators of cell growth and proliferation. It has been
reported that amplification of AKT2 is observed in pancreatic
cancer and mTOR/p70S6K signaling pathway is required for
pancreatic cancer cell proliferation. But the precise role of tuberin
in cancer development remains unclear. The purpose of this study
is to examine whether tuberin expression is expressed or lost in
pancreatic cancer tissues and cell lines, and to evaluate the corre-
lation between tuberin expression and clinocopathological features.
PATIENTS AND METHODS: First, immunohistochemical
analysis was performed in 42 pancreatic cancer tissues and 10
noncancerous pancreatic tissues with an anti-tuberin antibody.
Next, we examined mRNA expression of tuberin in pancreatic
cancer tissues by RT-PCR analysis. Correlation between tuberin
expression and clinocopathological features was evaluated. We also
examined tuberin expression in 6 pancreatic cancer cell lines by
Western blot and RT-PCR analysis. RESULTS: All the noncan-
cerous tissues showed strong expression, whereas 57% of
pancreatic cancer tissues showed reduced expression of tuberin.
Especially, 11 specimens of pancreatic cancer were stained negli-
gibly negative for tuberin. RT-PCR also showed weak to strong
expresson in cancer tissues. The reduced tuberin expression was
significantly correlated with patients with advanced pT factor
(3 and 4) of UICC classification (p=0.024) and male patients
(p=0.014). No statistical correlation with survival was found in
these series of immunohistochemstry. In pancreatic cancer cell
lines, the expression of tuberin was observed at almost equal level.
CONCLUSION: We demonstrated that tuberin expression was
reduced and associated with pT factor in pancreatic cancer. These
results suggest that tuberin plays a certain role in pancreatic cancer
development.
26 MODULATION OF PANCREATIC ABLATION
BY SIMULATED PORTAL CIRCULATION IN AN EX VIVO
PORCINE MODEL OF RADIOFREQUENCY ABLATION
Date RS2, McMahon R1, Siriwardena A2, (1) University
Department of Histopathology, Manchester Royal Infirmary;
(2) HPB Unit, Department of Surgery, Manchester Royal Infirmary,
Manchester, UK
INTRODUCTION AND AIM: We have reported the development
of an ex vivo porcine model for the study of radiofrequency ablation of
pancreatic parenchyma. This study evaluates the effects of variation
of target temperature, duration of ablation and heat-sink modulation
of portal circulation on thermal injury as a precursor to human trial.
PATIENTS AND METHODS: The starburst probe (RITA,
Mountainview CA) was used. Radiofrequency was applied to a
pre-marked area in the centre of the pancreatic head. The effect of
variations in temperature, duration and simulated portal circulation
were studied. Portal circulation was simulated by the use of a recir-
culating haemofiltration pump which perfused warm saline at a rate
of 100 ml/h. Post-ablation pancreatic biopsies incorporated the
duodenum, portal vein and bile duct. Control non-ablated biopsies
were from the tail of the pancreas. Temperatures between 70 and
100C were evaluated in 10 increments keeping duration constant
at 10 min. All experiments were repeated 5 times in separate
pancreata at each setting. RESULTS: The minimum temperature
needed to produce complete pancreatic ablation was 90C. There
was no additional benefit from ablation at higher temperatures
or greater duration. Simulated portal circulation had no effect on
ablation. Histologic analysis showed no evidence of thermal injury
to the duodenum. CONCLUSION: This study has demonstrated
that pancreatic parenchymal ablation is consistently achieved at
90C for 10 min. At this temperature there is no thermal injury to
the duodenum and this effect of radiofrequency was not affected
by simulated portal circulation. These findings are an important
step in the validation process towards radiofrequency ablation of
non-resectable pancreatic tumours in man.
27 EFFECT OF RETINOIC ACID ON P21WAF1
TURNOVER IN HUMAN PANCREATIC CANCER CELLS
Singh B1, Adrian T2, Roginsky AB1, Ding XZ1, Murphy RF1,
Talamonti MS1, Bell RH1, (1) Department of Surgery,
Northwestern University, Chicago, IL, Department of
Biomedical Sciences, Creighton University, Omaha, USA;
(2) Northwestern University Feinberg School of Medicine,
Surgical Research Departments of Surgery and Pathology,
Chicago, USA
INTRODUCTION AND AIM: Retinoic acid (RA) inhibits growth
by modulating cell cycle proteins, including p21, in various types
of cancer cells. The effects of RA on pancreatic cancer cell growth
are controversial. We investigated whether p21 was involved in
RA-induced growth inhibition, using conditions optimized for RA
response. RESULTS: In CD-18 cells, RA caused a massive but
transient 60-fold increase in p21 mRNA levels at 18 h, accompanied
by a three-fold increase in p21 protein levels. Levels of p21 mRNA
had normalized by 48 h, while p21 protein declined to levels 80%
lower than control. In HS766T cells the transient 8-fold increase
in p21 mRNA came later (24–48 h). No early increase in p21 protein
was seen in HS766T, but levels declined at later times. The decrease
of p21 protein levels following an increase in the mRNA suggested
that degradation of the protein was induced. The RA-induced
decrease in p21 was blocked by the proteosome inhibitor, MG132,
but not by the caspase-3 inhibitor III. These findings suggest
that the RA-induced p21 degradation is mediated by the proteo-
some but not by executioner caspases. However, we also detected
*32-fold increase in the mRNA expression of the recently discov-
ered p53 inducible ring finger protein (p53RFP), which is an
E3 ligase. This suggests that some form of p21 is targeted for
ubiquitination. CONCLUSION: These findings demonstrate
RA-induced p21 proteosomal degradation which may be ubiquitin-
independent. This decrease in p21 is unexpected in the face of
RA-induced growth arrest and may represent a cell-survival
mechanism.
28 TARGETED AND INDUCIBLE GENE/
IMMUNOTHERAPY OF PANCREATIC CARCINOMA
Wenger TU1, Ucur E1, Moldenhauer G2, Friess H3, Herr I1,
(1) CCU Pediatric Oncology, DKFZ, Heidelberg; (2) Moecular
Immunology, DKFZ, Heidelberg; (3) General Surgery, University
of Heidelberg, Heidelberg, Germany
INTRODUCTION AND AIM: Pancreatic carcinoma is a frequent
malignancy of the gartrointestinal system and associated with poor
prognosis. Due to the unsatisfactory response to conventional ther-
apy and 5-year survival rates below 15%, it ranks fifth among death
rates by cancer. Hence, new approaches for therapy of pancreatic
carcinoma are needed. PATIENTS AND METHODS: Our
combination gene/immunotherapy approach uses tumor necrosis
factor (TNF)-related apoptosis inducing ligand (TRAIL/Apo2L) as
therapeutic gene as TRAIL has been shown to induce apoptosis
specifically in cancer cells but not in normal cells. For tumor-specific
and inducible delivery patient-derived cytotoxic T cells (CTLs) are
transduced with recombinant lentiviral vectors which express TRAIL
under the control of a tetracycline-inducible promoter. The
manipulated CTLs are armed with bispecific antibodies able to
crosslink antigens commonly overexpressed in malignant cells (e.g.
Her2, EGFR) and the CD3 T-cell surface marker. Thus, the
nonspecific T cells are converted to tumor-specific TRAIL-KILLER
cells, which can home to the site of the tumor and metastases. After
switching on TRAIL expression by the antibiotic tetracycline,
apoptosis is induced in tumors. Our inducible TRAIL-based
immunotherapeutic approach may prove to be effective for targeting
a variety of pancreatic tumors with or without chemotherapy.
RESULTS: Current experiments focus on preclinical studies using
established cell lines in vitro and in vivo studies using xenografts
in nude mice. We have used stably transfected Jurkat T-cells for
preliminary experiments, showing that tet-induced TRAIL surface
overexpression on these cells efficiently induces apoptosis in target
cells, and are currently optimizing the lentiviral inducible expression
system.
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29 PROTEIN EXTERNALIZATION DURING
ANGIOGENESIS IN EXPERIMENTAL PANCREATIC AND
HEPATOCELLULAR CARCINOMA
Ryschich E, Knaebel HP, Bu¨chler M, Schmidt J, Department of
Surgery, University of Heidelberg, Heidelberg, Germany
INTRODUCTION AND AIM: The process of tumor angiogenesis
comprises a strong re-organization of intracellular proteins in endo-
thelial cells including protein externalization. Externalized proteins
could distinguish tumor endothelial cells from normal endothelium
and represent a possible vascular target for antitumoral therapy.
The externalization of several proteins such as actin, tropomyosin
and F0/F1-ATP-synthase has been found on proliferating endo-
thelial cells in vitro. The aim of the study was to identify whether
these proteins are externalized on tumor endothelium in experi-
mental pancreatic and hepatocellular cancer in vivo. PATIENTS
AND METHODS: Rat pancreatic (DSL6A) and hepatocellular
cancer (MH3924) were induced by subcutaneous inoculation of
tumor cells in male Lewis (DSL6A) and ACI (MH3924) rats. After
establishment of a solid tumor, 0.25 mg of mouse antibodies
against actin, tropomyosin, F0/F1-ATP-synthase, ICAM-1 (positive
control) and mouse immunoglobulin G (negative control) were
injected intravenously. Three tumor-bearing rats were used for
every single antibody. Tumors were removed 10 min after injection
of antibody. The tumors were cut and stained with anti-mouse
secondary antibodies. Additionally, intracellular staining was
performed by standard immunohistochemistry with identical anti-
bodies. RESULTS: The endothelium of venular endothelium was
strongly stained after injection of anti-ICAM-1 antibodies. No
cell membrane binding of anti-actin, tropomyosin or F0/F1-ATP-
synthase antibodies after intravenous injection was identified,
although a strong intracellular staining was found by immuno-
histochemistry. CONCLUSION: In contrast to in vitro data, actin,
tropomyosin and F0/F1-ATP-synthase are not externalized in vivo
and thus are unlikely to represent a vascular target for anticancer
therapy.
30 CT ANTIGEN EXPRESSION IN PANCREATIC
ADENOCARCINOMA AND NORMAL PANCREAS
Schmitz-Winnenthal FH1, Z
0
graggen K5, Volk C1, Galindo LV1,
Tempia A2, Rimoldi D3, Romero P4, Bu¨chler MW1, (1) Department
of Surgery, University of Heidelberg, Heidelberg, Germany;
(2) Department of Surgery, University of Lausanne, Lausanne;
(3) Molecular Tumor Immunology Group, Ludwig Institute for
Cancer Research; Lausanne; (4) Division of Clinical Onco-
Immunology, Ludwig Institute for Cancer Research; Lausanne;
Switzerland; (5) Klinik Beau-Site Hirslanden, Department of
Surgery, Bern, Switzerland
INTRODUCTION AND AIM: Cancer testis (CT) antigens are
antigens shared by a variety of malignant tumors, but usually not by
normal tissue. The exceptions are germ cells in testis. Restricted
expression in neoplastic tissues and immunogenic features make
CT antigens ideal for use in immunotherapy. Effective immuno-
therapy requires antigenic peptides with binding motifs restricted
to specific MHC alleles. Pancreatic cancer has been poorly studied
with regard to CT antigen expression. The investigation of a selected
panel of CT antigens and tumor-related antigens in pancreatic cancer
that have been shown to elicit an efficient immunogenic response
in other malignancies was the aim of this study. PATIENTS AND
METHODS: Pancreatic adenocarcinoma samples (n=76) were
obtained intraoperatively, control tissues (n=5) were collected from
cadaveric donor and from patients with chronic pancreatitis. CT
antigen expression of MAGE A1, MAGE A3, MAGE A4, MAGE
A10, LAGE 1, NY-ESO-1, SSX-2, and SSX-4 were investigated.
Tumor-related antigens PRAME, NA-17A, as well as HERV-K-Mel
expression were also assessed by PCR. Western blot analysis and
sequencing were performed to assess the expression of SSX-4 in
neoplastic and normal pancreatic tissues. RESULTS: SSX-4 was
detected in 10.5% of the tested pancreatic adenocarcinoma speci-
mens, the rest of the explored CT antigens were expressed in53% of
the samples. HERV-K-Mel was found positive in 20% of the tested
pancreatic adenocarcinoma samples. Surprisingly, SSX-4 (100%)
and faintly SSX-2 expression (60%) was detected in normal
pancreatic tissue; Western blot analysis and sequencing confirmed
the expression of SSX-4 in both malignant and normal pancreatic
samples. CONCLUSION: The explored panel of CT antigens
showed an overall low expression rate (55%). SSX-4 expression
in both neoplastic and normal pancreatic tissue may indicate
immunological relevance. However, HERV-K-Mel is expressed
with a relatively high prevalence and may be a candidate for specific
immunotherapy in a large subgroup of pancreatic cancer patients.
31 DENDRITIC CELLS REDUCE NUMBER AND
FUNCTION OF CD4+CD25+ CELLS IN CYTOKINE-INDUCED
KILLER CELLS DERIVED FROM PATIENTS WITH
PANCREATIC CARCINOMA
Schmidt J, Ma¨rten A, Bu¨chler M, Department of Surgery,
University of Heidelberg, Heidelberg, Germany
INTRODUCTION AND AIM: CD4+CD25+ cells are described
as professional regulatory/suppressor T cells that are crucial for
the prevention of spontaneous autoimmune diseases. They play an
important role in maintaining a balanced peripheral immune system.
On the other hand, it has been suggested that regulatory T cells
(Treg) suppress antitumor immune responses after tumor-specific
vaccinations. PATIENTS AND METHODS: Therefore, we deter-
mined the percentage of regulatory T cells in cytokine-induced
killer cells (CIK cells), an effector cell population with high impact
for adoptive immunotherapeutic strategies. RESULTS: CIK cells
showed strong induction of CD4+CD25+ cells with high secretion
of IL-10 after nonspecific stimulation of the TCR complex and
stimulation with IL-2. Depletion of CD25+ cells led to an increase
in cytotoxic activity and a reduction of IL-10 release. A more
pronounced reversal of suppression could be induced by co-culture
of CIK cells with dendritic cells (DCs). After co-culture of CIK cells
with DCs, the number of CD4+CD25+ cells as well as the IL-10
concentration in the supernatant decreased and the cytotoxic activity
against pancreatic carcinoma cells increased. This was shown for
cells from healthy donors as well as for cells from patients with
pancreatic carcinoma. CONCLUSION: In conclusion, our estab-
lished effector cells possess some regulatory features induced by
unspecific TCR activation that could be prevented by co-culture with
DCs. CIK cells have desirable properties for immunotherapeutical
approaches, especially after co-culture with DCs, which could be
used additionally for induction of a specific immune response.
32 MOLECULAR CANCER DIAGNOSTICS OF
PANCREATIC TUMOURS USING MICROARRAY
TECHNOLOGIES
Hoheisel J1, Beier V1, Kusnezow W1, Kleeff J2, Bauer A1, Lyko F3,
Friess H2, (1) Funktionelle Genomanalyse, DKFZ, Heidelberg;
(2) Department of General Surgery, University of Heidelberg;
(3) Epigenetics, DKFZ, Heidelberg, Germany
INTRODUCTION AND AIM: The diagnosis of ductal adeno-
carcinoma of the pancreas is associated with a poor prognosis, an
increasing incidence and no or only ineffective means of treatment.
We are developing and evaluating chip-based diagnostic analyses at
the level of epigenetic variations, changes in transcript levels and
actual protein expression. PATIENTS AND METHODS: DNA-
methylation patterns are analysed with in situ synthesised oligo-
nucleotide arrays that query the promoter of currently some 250
genes. Transcript profiling is performed on a microarray that consists
of PCR products, which represent about 3500 human genes that
are known to be differentially transcribed in pancreatic cancer cells
and thus expected to show a representative expression pattern in
both ductal adenocarcinoma and cystic lesions. Based on earlier
transcriptional analyses, we selected 900 genes, which exhibited a
significant increase of RNA levels. From their sequences, peptides
were selected and used for immunisation of rabbits. The resulting
antibodies are also arrayed on microscopic slides for an investigation
of variations in the protein expression. In addition, we isolate
recombinant antibodies, which are specifically binding to either
normal or tumour cells. RESULTS: Microarray experiments on
various samples were performed and allowed a classification of dif-
ferent types of pancreas lesions. Genes or proteins were identified
that are highly associated with the occurrence of tumours and provide
reasonable chances of affecting pathways that are essential for
pancreatic tumours. Analyses of serum samples and other body fluids
for the establishment of an early, non-invasive diagnostic assay are
ongoing and will be discussed at the meeting. CONCLUSION:
The data resulting from our studies will allow a detailed analysis of
regulative factors, which are critical to pancreatic tumours, as well
as the identification of highly relevant molecule interactions. In
addition, diagnostic assays are established, which might be of
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significant clinical utility to detect cancer cells in tissue from patients
with different types of pancreatic carcinoma and to draw prognostic
conclusions based on their molecular appearance.
33 PROFILING OF CYSTIC NEOPLASMS OF THE
PANCREAS USING MICROARRAY TECHNOLOGY
Bauer A1, Fellenberg K1, Friess H2, Kleeff J2, Bier M1, Hoheisel JD1,
(1) Funktionelle Genomanalyse, DKFZ Heidelberg; (2) Division
of General Surgery, Universita¨t Heidelberg, Heidelberg, Germany
INTRODUCTION AND AIM: Cystic pancreatic neoplasms
account for approximately 5% of primary malignancies of the
pancreas and may be benign, pre-malignant or malignant. These
types of pancreatic tumours are characteristic for the better prognosis
compared to the more aggressive ductal adenocarcinoma. In this
study, we are developing and evaluating a DNA diagnostic chip with
about 3500 human genes known to be differentially transcribed
in pancreatic cancer cells and thus expected to show a representative
expression pattern in both ductal adenocarcinoma and cystic lesions.
PATIENTS AND METHODS: cDNAs representing different
human genes were PCR-amplified, purified and robotically arrayed
onto slides with an epoxy surface. Fluorescently labelled cDNA
samples were prepared from total RNA isolated from cells of human
pancreas tissue by incorporation of labelled dCTPs during reverse
transcription. RESULTS: Currently, we can detect transcript
variations with only 5 mg of total RNA as starting material with no
need for amplification. Microarray experiments on various samples
are being performed and analysed, allowing classification of different
types of pancreas lesions and the identification of potential targets
as a means of eventually developing new modes of treatment.
CONCLUSION: The resulting diagnostic DNA chip will be of
significant clinical utility to detect cancer cells in tissues from patients
with different types of pancreatic carcinoma and to draw prognostic
conclusions based on their molecular appearance. Furthermore,
comparative studies on transcriptional profiling and actual protein
expression by means of complex DNA and antibody microarrays are
under way. Combining these data with clinical information permits
the definition of subgroups within an analysed cohort and may
eventually provide a robust means for diagnosis and prognosis as well
as the identification of highly relevant molecular pathways.
34 INHIBITION OF CYTOTOXIC GAMMA/DELTA T
CELLS BY PANCREATIC CARCINOMA PATIENTS’
DERIVED SOLUBLE MIC+ SERUM COULD BE RESTORED
BY CAPTURING SOLUBLE MIC WITH ANTIBODIES
Salih H1, Ma¨rten A2, Steinle A1, Bu¨chler MW2, Schmidt J2,
(1) Department of Internal Medicine, University of Tu¨bingen,
Tu¨bingen, Germany; (2) Department of Surgery, University of
Heidelberg, Heidelberg, Germany
INTRODUCTION AND AIM: NKG2D is known to stimulate
tumor immunity through activation of T cells, NK cells and gamma/
delta T cells. Its ligands MICA/B and ULBPs have been shown to
be broadly expressed on epithelial tumors. Shedding of MICA is
suspected to modulate NKG2D-mediated tumor immune surveil-
lance in a negative way. PATIENTS AND METHODS: Sera
from 55 patients with pancreatic adenocarcinoma were tested
for presence of soluble MICA/B (sMIC). NK cells or gamma/delta
T cells were used as effector cells against pancreatic carcinoma
cells in cytotoxicity assays in the presence of either MIC-positive
or -negative serum. RESULTS: Patients showed elevated serum
levels of sMICA/B. sMICA/B level correlated with tumor grade,
grade of differentiation and tumor stage. NK92 cells were inhibited
after addition of sMIC+ patients’ sera. Pancreatic tumor cells
expressing MIC and or ULBPs were lysed by NK92 cells in an
NKG2D-dependent fashion, this could be blocked by addition of
sMIC+ sera. Gamma/delta T cells killed pancreatic tumor cells in a
NKG2D-dependent way. The inhibition of cytolysis in the presence
of sMIC+ sera was mediated by sMIC. Addition of anti-MIC to
the patients’ sera in cytotoxicity assays restored the cytolytic activity
nearly completely. CONCLUSION: Pancreatic carcinomas express
MIC and shed sMIC. This phenomenon is dependent on tumor
grade, differentiation and stage. sMIC inhibits cytotoxic activity of
NK cells as well as gamma/delta T cells. Gamma/delta T cells
lyse pancreatic tumor cells after recognition of MIC or ULBPs via
NKG2D receptor; this could be restored by capturing of sMIC by
specific antibodies.
35 A NEW THERAPEUTIC STRATEGY FOR THE
TREATMENT OF PANCREATIC CANCER BY A
CONDITIONALLY REPLICATION-COMPETENT HSV-1
VECTOR
Kami K1, Doi R1, Ito D1, Miyatake SI2, Imamura M1,
(1) Department of Surgery and Surgical Basic Science, Kyoto
University, Kyoto, Japan; (2) Department of Neurosurgery,
Osaka Medical College, Osaka, Japan
INTRODUCTION AND AIM: In this study, we constructed an
oncolytic herpes simplex virus 1 (HSV-1) vector (d120.survE)
in which the survivin promoter drives expression of ICP4, a major
transactivating factor for viral genes, so that replication of the vector
is restricted to survivin-expressing cells. Survivin is not expressed
in normal adult tissues, but it becomes highly expressed in trans-
formed cell lines and in most of the common human cancers
including pancreatic cancer. Then, we assessed the ability of
d120.survE to inhibit the growth of pancreatic cancer cells in vitro
and in vivo. PATIENTS AND METHODS: A 397-bp survivin
promoter was characterized using luciferase reporter assays, and was
cloned into the thymidine kinase (tk) gene of mutant HSV-1 d120,
deleted for both copies of the ICP4 gene. This vector also contains
the E. coli LacZ gene under control of the tk promoter. ICP4
and LacZ expression in the cells infected by d120.survE were
examined by Western blot analysis and X-gal staining. The ability of
d120.survE to replicate specifically in survivin-expressing cells was
examined by a viral single-step growth experiment in three human
pancreatic cancer cell lines (Panc-1, SUIT-2, and AsPC-1). The
in vitro cytotoxic activity of d120.survE was examined by infecting
the same cell lines with the vector at a low multiplicity of infection
(0.001 to 10). For in vivo studies, nude mice harboring AsPC-1
tumors subcutaneously recieved twice on days 0 and 7 intra-
neoplasmic injection of 106 plaque-forming units of d120.survE.
The tumor sizes were measured every 5 days. Expression of the
lacZ gene was also examined by X-gal staining. RESULTS: ICP4
and LacZ were expressed in pancreatic cancer cells infected by
d120.survE. The ability of d120.survE to replicate and the cytotoxic
activity of d120.survE were correlated with survivin promoter
activity of the host cells. There were 60% and 10% cells surviving
respectively in Panc-1 (low expression of survivin) and AsPC-1 (high
expression of survivin) cells infected by d120.survE at an MOI of
0.01 on day 7 post-infection compared to those of mock-infected
cells. Subcutaneous tumors treated with d120.survE were signifi-
cantly smaller than control tumors by day 30 post-infection. Positive
X-gal staining was also observed in the tumor nodule which
was challenged with this viral vector. CONCLUSION: A con-
ditional replication-competent HSV-1 vector regulated by the sur-
vivin promoter may be a new therapeutic strategy for treatment
of pancreatic cancer.
36 PLASMA LEVELS OF MATRIX
METALLOPROTEINASE-7 CAN BE USED TO
DIFFERENTIATE BETWEEN PERIAMPULLARY
CARCINOMA AND CHRONIC PANCREATITIS
Kuhlmann KFD1, van Till ORC1, Boermeester M1, Tsvetanova I3,
Offerhaus J2, ten Kate F2, Busch O1, van Gulik T1, Gouma D1,
Crawford H3, (1) Department of Surgery, Academic Medical
Center, Amsterdam; (2) Department of Pathology, Academic
Medical Centre; Amsterdam, The Netherlands; (3) Department
of Pharmaceutical Sciences, State University of New York at Stony
Brook, New York, USA
INTRODUCTION AND AIM: The radiological differentiation
between periampullary carcinoma and chronic pancreatitis (CP)
with an inflammatory mass is difficult. Consequently, 5–10% of
pancreatic resections are performed for CP. The aim of this study
was to test whether the levels of matrix metalloproteinase-7
(MMP-7), a secreted protyolytic enzyme, can distinguish between
these two disorders. PATIENTS AND METHODS: MMP-7 levels
in plasma, pancreatic and duodenal juice were analyzed in 22 patients
who underwent pancreaticojejunostomy for CP and 60 consecutive
patients who underwent exploratory laparotomy for a suspected
periampullary malignancy. RESULTS: MMP-7 plasma levels
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were significantly higher in patients with pancreatic carcinoma
(1.99 ng/ml, range 0.50–10.18, n=28) and distal cholangiocarci-
noma (1.83 ng/ml, range 0.66–6.44, n=10) compared to those
with CP (0.83 ng/ml, range 0.25–3.53, n=27). MMP-7 levels in
pancreatic juice were significantly elevated in pancreatic cancer
(143 ng/mg protein, range 0.6–9789, n=17) compared to those
in CP (15 ng/mg protein, range 0–2380, n=31). MMP-7 levels in
duodenal juice did not significantly differ between groups. Plasma
levels of 5 patients who underwent a resection for an inflammatory
mass were comparable with those of the other patients with
CP (1.16 ng/ml, range 0.79–2.16). When a plasma threshold of
1.5 ng/ml was used in patients who underwent exploration, the
positive predictive value for the determination of periampullary
(pancreatic and distal cholangio) carcinoma was 96% with a speci-
ficity of 80%. The sensitivity was 63%. CONCLUSION: Plasma
MMP-7 levels can be used as a marker for pancreatic cancer and in
particular to differentiate between periampullary cancer and CP
in cases of diagnostic uncertainty by conventional diagnostics.
37 FUNCTIONAL TUMOR REACTIVE T CELLS
IN BONE MARROW AND BLOOD OF PANCREATIC
CANCER PATIENTS
Schmitz-Winnenthal FH1, Beckhove P2, Volk C1, Weitz J1, Nummer
D2, Galindo LV1, Bu¨chler MW1, Schirrmacher V2, Z’graggen K3,
(1) Department of Surgery, University of Heidelberg, Heidelberg;
(2) Division of Cellular Immunology, German Cancer Research
Center, Heidelberg, Germany; (3) Department of Surgery, Klinik
Beau-Site Hirslanden, Bern, Switzerland
INTRODUCTION AND AIM: Memory T cells specifically reactive
to tumor antigens should be an ideal source to generate therapeutic
effector cells against pancreatic cancer. To our knowledge func-
tionally active, specific memory T cells have not been demonstrated
in pancreatic cancer patients. To investigate if functional memory
T cells are present in the bone marrow (BM) of pancreatic cancer
patients, we performed in vitro stimulation with tumor-associated
antigens presented by autologous dendritic cells (DCs). PATIENTS
AND METHODS: DCs and T cells were generated in a 14-day
culture with GM-CSF and IL-4 (DCs) and/or IL-2, IL-4, IL-7
(T cells) from BM-derived CD34+ progenitor cells of 35 patients
with pancreatic carcinoma and chronic pancreatitis. DCs were
pulsed with lysate from autologous tumor cells, Muc I peptide frag-
ments and PBMCs (peripheral blood mononuclear cells as negative
controls). Tumor specific T-cell response was evaluated in a single-
cell interferon-a, IL-4, IL-10 and IL-12 release immunospot assay
(Elispot). Cytotoxicity of CD8+ T cells against primary cultured
tumor cells was measured by a functional DNA release, and trypan
blue staining assay. RESULTS: In the individual patient, T cells
stimulated by tumor lysate pulsed DCs as well as DCs pulsed with
Muc I peptide showed a significantly higher response in the INF-a
Elispot assay compared with T cells stimulated by PBMC-lysate
pulsed DCs. The tumor specific T-cell frequency found in the
bone marrow was consistently high (49/105 to 109/105) in all
patients compared with the response found in the peripheral blood
(9/105 to 53/105; p50.05 to p50.001). In the cytotoxicity assay,
the response was significantly higher when T cells were stimulated
with tumor lysate pulsed DCs compared with PBMC-lysate pulsed
DCs. CONCLUSION: Our data indicate for the first time a regular
occurrence of tumor antigen specific T-cell responses during
the course of pancreatic cancer that lead to the generation and
enrichment of functional tumor cell-reactive memory T cells in the
bone marrow. The bone marrow may therefore be considered
an important lymphoid organ for the induction or maintenance of
anti-tumor immune responses in pancreatic cancer.
38 DNA CONTENT AND SURVIVAL RATES OF
PATIENTS WITH PANCREATIC CANCER: A PROSPECTIVE
STUDY OF 65 CASES
Al-Abadi HPD2, Abou-Rebyeh H1, Schumacher G2, (1)
Gastroenterologie-Hepatology, Charite Campus Virchow-Klinikum;
(2) Allgemein, Visceral, Transplantationschirurgie, Charite Campus
Virchow-Klinikum, Berlin, Germany
INTRODUCTION AND AIM: Nuclear DNA content and
pathology are considered to be prognostically relevant to several
solid tumors, but controversial findings have emerged from
pancreatic carcinoma (PC). PATIENTS AND METHODS: During
the 3-year period between January 1999 and December 2001 we
enrolled a total of 64 patients with histologically proven ductal
adenocarcinoma of the pancreas in a prospective study. DNA ploidy
was assessed by image cytometry in cytological specimens obtained
from ERCP by aspiration and brush cytology. All 64 patients were
followed up till death (n=48) or in case of survival (n=16) a mean
follow-up period was 12+9 months. Survival was calculated by
using the Kaplan-Meier method. Risk factors were identified with
Cox regression analysis. RESULTS: DNA cytometry revealed
aneuploid (n=47) as well as polyploid (n=15) and dilpoid (n=2)
pancreatic cancer. Resection margins, lymph node status and tumor
differentiation were independent prognostic factors. Patients with
diploid and polyploid pancreatic adenocarcinoma had significantly
longer survival (median survival was 35 months) compared to 15
months in patients suffering from aneuploid pancreatic cancer. This
diploidy associated with survival benefit persisted after adjustment
for prognostic factors including tumor size, margins, lymph
node status and pathological stage. CONCLUSION: Patients with
pancreatic adenocarcinoma will survive longer if their cancer is
diploid or polyploid and will have a very poor prognosis if afflicted
with DNA aneuploid cancer. Based on the analysis carried out the
authors conclude that the main prognostic factor for long-term
survival is DNA ploidy itself showing close association with natural
development and tumor biology. The predictive value of DNA ploidy
is present in patients with resectable or unresectable tumor stage.
The results may be helpful for predicting life expectancy, determin-
ing treatment strategies and designing future clinical trials.
39 THE INHIBITION OF SRC TYROSINE KINASE
ENHANCES THE EFFICACY OF CHEMOTHERAPEUTIC
AGENTS AGAINST PANCREATIC CARCINOMA CELLS
Bruns CJ2, Ischenko I1, Papyan A1, Guba M1, Green T3, Jauch KW1,
(1) Surgery, University of Munich-Großhadern; (2) Department
of Surgery; University of Munich-Großhadern, Munich, Germany;
(3) AstraZeneca, Macclesfield, Alderley Park, UK
INTRODUCTION AND AIM: Pancreatic cancer is one of the
most aggressive tumors and resistant to almost all cytotoxic agents.
The majority of pancreatic cancer cell lines over-express Src tyrosine
kinase (Src kinase). Here we explored whether inhibition of the
Src can reduce resistance of the human pancreatic carcinoma cells to
chemotherapy in vivo and in vitro. PATIENTS AND METHODS:
We used an orthotopic animal model, immunohistochemical analy-
ses of pancreatic tumor samples and MTT assays to evaluate in vivo
and in vitro the effect of Src to reduce chemotherapy resistance
in pancreatic tumor cells and human pancreatic tumors growing
orthotopically in nude mice. RESULTS: The pre-existing resistance
to chemotherapeutical agents such as gemcitabine and 5-FU in
L3.6pl and AsPc human pancreatic cell lines was found to be asso-
ciated with expression of the active Src kinase. IC50 doses detected
by MTT cells viability assay of gemcitabine and 5-FU were
0.0487 mg/ml and 10.1 mg/ml for L3.6pl cells and 452.6 mg/ml and
112.9 mg/ml for AsPc, respectively. IC50 doses after combination of
AZM with gemcitabine or 5-FU were significantly reduced in L3.6pl
(0.0272 mg/ml and 0.532 mg/ml) and in AsPc (56.4 mg/ml and
24.3 mg/ml), respectively. The sensitizing effect of Src kinase inhi-
bition towards cytotoxic agents such as gemcitabine was confirmed
in vivo: the amount of TUNEL-positive apoptotic tumor cells was
significantly higher in pancreatic tumors following orthotopic cell
injection in nude mice when the animals were treated with AZM for
1 week at the end of a treatment period with increasing doses of
gemcitabine as compared to those only treated with increasing doses
of gemcitabine. Furthermore, treatment of the nude mice 7 days after
orthotopic injection of L3.6pl human pancreatic cells with low dose
gemcitabine (50 mg/kg, twice-weekly i.p.) in combination with AZM
(50 mg/kg, daily oral) led to a 93.1% reduction of primary pancreatic
tumor growth comparable with those treated with high dose gemci-
tabine (100 mg/kg, twice-weekly i.p.) in combination with AZM
(50 mg/kg, daily oral) (92% reduction of primary pancreatic tumor
weight). CONCLUSION: In summary, our data indicate that inhi-
bition of Src significantly enhances the anti-tumor efficacy of stan-
dard chemotherapy in human pancreatic cancer. In consequence,
the inhibition of Src can significantly reduce the dose of the cytotoxic
agents such as gemcitabine without any deficit in their anti-tumor
efficacy, but less side effects.
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40 GAIN OF CHROMOSOME 8Q DETECTED BY
COMPARATIVE GENOMIC HYBRIDISATION (CGH) IS
ASSOCIATED WITH POOR SURVIVAL IN PATIENTS
WITH RESECTABLE PANCREATIC CANCER
Schleicher C2, Poremba C1, Wolters H2, Boecker W3, Senninger N2,
Colombo-Benkmann M2, (1) Institute of Pathology, University of
Du¨sseldorf, Du¨sseldorf, Germany; (2) Department of General
Surgery, University of Mu¨nster; (3) Institute of Pathology,
University of Muenster, Muenster, Germany
INTRODUCTION AND AIM: The objective of this study was
to detect specific genomic alterations involved in initiation and
progression of pancreatic cancer (PCA). Chromosomal imbalances
were correlated with histopathological and clinical data to verify
the prognostic significance of identified cytogenetic changes.
PATIENTS AND METHODS: Paraffin-embedded specimens
from 33 patients with PC were investigated by comparative genomic
hybridisation (CGH). Microdissection was used for separation of
PC from normal cells before isolation of DNA, nick end labeling
and hybridization were performed according to standard protocols.
Aberrations were correlated with histopathological staging (UICC
2002) by univariate and multivariate anaylsis using log rank test
and Cox regression, respectively. Survival rates were plotted using
the Kaplan-Meier method. RESULTS: 28 (85%) PC showed
chromosomal aberrations. Gains of chromosomal material were
most frequently identified on 8q (42%), 13q (30%), 18p (21%), and
3q (18%). Genetic losses were frequently detected on 1p (45%),
22 (42%), 19 (36%), 17p (27%), 18q and 8p (15% each) and
3p (12%). Losses of 8p (n=5) and 3p (n=4) were only detected
in stage III and IV PC (p50.05). Median survival time of all
patients was 13 months. Median survival time of patients with
aberration of 8q (n=14) was 8.5 months compared to 16 months in
patients without gain of 8q (n=19; p=0.029). CONCLUSION:
The chromosomal regions containing genetic alterations represent
potential loci for new target genes in PC. The significant correlation
of gain of chromosome 8q with short survival time suggests that
potential new prognostic markers could be located on this chromo-
somal region.
41 TRAF2 AND THE CD95 DEATH RECEPTOR MEDIATE
INVASIVENESS OF PANCREATIC CANCER CELLS
Trauzold A1, Ro¨der C1, Sipos B2, Karsten K1, Arlt A3, Kalthoff H1,
(1) Sektion Molekulare Onkologie, UKS-H, Klinik f. Allgemeine
Chirurgie u. Thoraxchirurgie; (2) Institut f. Allgemeine Pathologie,
UKS-H; (3) Labor f. Molekulare Gastroenterologie, UKS-H, 1.
Med. Klinik, Kiel, Germany
INTRODUCTION AND AIM: Pancreatic ductal adenocarcinoma
is characterized by poor prognosis due to apoptosis resistance and
its highly metastatic potential. Anti-apoptotic changes in pancreatic
tumor cells include high constitutive and death receptor-induced
activity of the transcription factor NF-kappaB. TRAF2 is an
adaptor molecule involved in death receptor-mediated NF-kappaB
induction. The aim of this study was to investigate the role of
TRAF2 in the pathophysiology of pancreatic adenocarcinoma.
PATIENTS AND METHODS: Expression of TRAF2 was detected
by immunohistochemistry and by Western blot analysis. Low
TRAF2-expressing Colo357 cells were transfected with a TRAF2-
expression plasmid and the effects were analyzed using an in vitro
invasion assay and the ‘JAM’-apoptosis assay. Activation of tran-
scription factors was detected by EMSA. Secretion of IL-8, uPA,
MMP-9, and MMP-2 was analyzed by ELISA or by zymography.
RESULTS: TRAF2 was constitutively overexpressed in 34 of 36
pancreas adenocarcinomas and in pancreatic tumor cell lines.
Transfection and overexpression of TRAF2 in apoptosis-sensitive
Colo357 cells led to resistance against CD95-induced apoptosis,
increased constitutive NF-kappaB and AP-1 activity, higher
secretion of MMP-2, MMP-9, uPA, and IL-8, as well as enhanced
invasive growth. Stimulation of Colo357/TRAF2 cells with CD95-
ligand resulted in an additional NF-kappaB and AP-1 induction,
secretion of IL-8 and uPA, and a further increased invasiveness.
CONCLUSION: TRAF2 is involved in establishing the malignant
phenotype of pancreatic carcinoma cells. Overexpression of TRAF2
switches CD95-induced apoptosis towards survival and enhanced
invasiveness after stimulation of this death receptor. The high
incidence of TRAF2 positivity in clinical tumor samples further
underlines its pathophysiological importance.
42 AN ANALOGUE OF SANSALVAMIDE POTENTLY
INHIBITS PANCREATIC CANCER CELL GROWTH
THROUGH G0/G1 CELL CYCLE ARREST
Ujiki MB1, Adrian T2, Ding XZ1, Liu S1, Gu W1, Roginsky A1,
Salabat MR1, Silverman R1, Talamonti MS1, Bell RH1, (1)
Department of Surgery and Robert H. Lurie Comprehensive Cancer
Center, Feinberg School of Medicine, Northwestern University,
Chicago, IL; (2) Northwestern University Feinberg School of
Medicine, Surgical Research Departments of Surgical and
Pathology, Chicago, USA
INTRODUCTION AND AIM: Patients with pancreatic cancer
have little hope for cure because no effective therapies are available.
Gemcitabine is the first-line chemotherapeutic agent used, but has
little impact on survival. Sansalvamide A is a product of a marine
fungus and has been used to develop a novel family of analogues
for use as potential chemotherapeutic drugs. We hypothesized
that these peptides would inhibit human pancreatic cancer cell
growth in vitro. After screening for anti-cancer effects the present
study focused on the most potent of these analogues. PATIENTS
AND METHODS: Two human pancreatic cancer cell lines
(AsPC-1 and S2-013) were treated with various concentrations
(0.1–100 mM) of analogue. Proliferation was measured by 3H-
thymidine incorporation and cell counting at different time points
(24–72 h). Cell cycle analysis was determined by flow cytometry
with propidium iodide DNA staining. Morphological changes
were observed using light microscopy. RESULTS: The analogues
caused both time- and concentration-dependent inhibition of DNA
synthesis (85% decrease in AsPC-1, p50.01 and 82% decrease in
S2-013, p50.01 at 24 h with 10 mM) and cell proliferation (82%
decrease in AsPC-1, p50.001 and 69% decrease in S2-013,
p50.001 at 72 h with 10 mM). The peptides induced G0/G1 phase
cell cycle arrest (AsPC-1 control 78.8% vs treated 86.7%, p50.01;
S2-013 control 55.8% vs treated 75.9%, p50.01). At 24 h,
obvious morphological changes could be seen through light
microscopy at a concentration of 10 mM. CONCLUSION: These
novel peptides inhibit growth of pancreatic cancer cells through
G0/G1 arrest and may be valuable for the treatment of pancreatic
cancer.
43 EPITHELIAL–STROMAL INTERACTIONS IN
PANCREATIC CANCER: THE ROLE OF TENASCIN C
AND ANNEXIN II
Esposito I1, Penzel R1, Bergmann F1, Giese N2, Kleeff J2, Friess H2,
Schirmacher P1, (1) Institute of Patholog; (2) Department of
General Surgery, University of Heidelberg, Heidelberg, Germany
INTRODUCTION AND AIM: Epithelial–stromal interactions
are relevant to the progression of pancreatic ductal adenocarci-
noma (PDAC). Tenascin C (TNC) is an extracellular matrix
protein with anti-adhesive and pro-invasive properties. The aim of
this study was to elucidate the role of TNC and its cell surface
receptor annexin II in the progression of PDAC. PATIENTS
AND METHODS: Real-time quantitative PCR was used to eval-
uate the levels of TNC mRNA. The transcriptional levels of TNC
splice variants were assessed by PCR. Immunohistochemistry
was used to localize the expression of TNC and annexin II.
RESULTS: TNC mRNA was overexpressed in pancreatic cancer
tissues (4-fold) in comparison to the normal pancreas and it was
demonstrated in 4 of 7 pancreatic cancer cell lines. TNC large
splice variants were present in pancreatic cancer tissues and cell
lines, but not in the normal pancreas. TNC mRNA was also
detected in pancreatic stellate cells, where it increased under
TNF-alpha stimulation. TNC expression was mostly stromal and
increased in frequency in the progression from PanIN-1 lesions to
PDAC. Annexin II was expressed in almost all the PanIN lesions
and in all the cancer samples. A redistribution of annexin II from
the cytoplasm to the cell membrane was observed in the progres-
sion from low-grade PanINs to PDAC. CONCLUSION: TNC is
overexpressed in the stroma of PDAC, possibly under the influence
of cytokines. The increase in TNC expression in the subsequent
steps of pancreatic tumor progression and the parallel redistribu-
tion of annexin II to the cell membrane suggests an involvement
of the two proteins in the establishment of a tumor-favorable
microenvironment.
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44 ANTISENSE OLIGONUCLEOTIDES TARGETED TO
K-ras POINT MUTATION IN HAMSTER EXPERIMENTAL
PANCREATIC CANCER MODEL – CAN IT INHIBIT THE
GROWTH OF 5-FU- AND MMC-RESISTANT METASTATIC
AND REMETASTATIC CELL LINES?
Morioka CY1, Machado MCC1, Saito S2, Ohzawa K2, Matheus AS3,
Jukemura J1, Cunha JEM1, Watanabe A1, (1) Department of
Surgery, University of Sa˜o Paulo, Sa˜o Paulo, Brazil; (2) 3rd
Department of Internal Medicine, Toyama Medical and
Pharmaceutical University; (3) Department of Surgery, Toyama
Medical and Pharmaceutical University; Toyama, Japan
INTRODUCTION AND AIM: New genes have been discovered
day after day and some of them have been related to disease states,
including pancreatic cancer. K-ras point mutation at codon 12 has a
relationship of490% with pancreatic cancer. Cancer therapy should
also include the treatment of metastatic disease because it is known
that properties of metastatic cells may vary considerably from those
of the primary tumor. The aim was to verify whether the same drugs,
which can inhibit the tumor growth in the parental cell line, could
inhibit the pancreatic metastatic and pancreatic remetastatic cell
lines at the same concentrations and to compare the inhibition with
antisense oligonucleotides mismatched to K-ras gene, in Syrian
golden hamsters. PATIENTS AND METHODS: HaP-T1, a BHP-
induced hamster pancreatic cancer cell line, MS-PaS-1 (a metastatic
cell line established from ‘return trip’ metastases from the liver to the
pancreas) and MS-PaS-2 named as ‘remetastatic cell line’ (i.e.
metastases from MS-PaS-1) were used. MTT and MTT-agarose
assays were performed, using 5-fluorouracil (5-FU), mitomycin C
(MMC) and antisense oligonucleotide specific to K-ras oncogene.
RESULTS: The inhibitory concentration (IC50) of 5-FU, which
inhibited the HaP-T1, had to be increased by 50-fold to inhibit
MS-PaS-1 and 100-fold to inhibit MS-PaS-2. MMC had to be
increased by 10-fold to inhibit MS-PaS-1 and 50-fold to inhibit
MS-PaS-2. However, ID50 was the same when antisense oligo-
nucleotide was tried in these 3 cell lines. CONCLUSION: Antisense
oligonucleotide targeted K-ras gene may be a good choice for therapy
because it could inhibit the growth in metastatic and remetastatic
pancreatic cells as well as in primary tumor cells.
45 ROLE OF IMMUNOHISTOCHEMICAL AND
MOLECULAR IDENTIFICATION OF HER-2 GENE IN
HUMAN PANCREATIC CANCER
Borka K2, Szijjarto A1, Kaliszky P1, Kiss A2, Schaff Z2, Kupcsulik P1,
(1) 1st Department of Surgery; (2) 2nd Department of Pathology,
Semmelweis University, Budapest, Hungary
INTRODUCTION AND AIM: The expression of epidermal
growth factor receptor-2 (HER-2) has a role in malignant transfor-
mation and metastasis formation. Overexpression has also been
demonstrated in adenocarcinomas of the pancreas but the signifi-
cance is unclear. Following the success of HER-2 neutralizing anti-
body treatment in breast cancer, some authors reported results of
the combinations of trastuzumab (Herceptin) and gemcitabine in
HER2-overexpressing patients with pancreatic carcinoma. However,
it is still controversial whether gene amplification or protein detection
is required for the initiation of the treatment. The aim was to
correlate HER-2 DNA amplification and protein overexpression
in human pancreatic adenocarcinomas. PATIENTS AND
METHODS: 27 pancreatic tumors were immunostained by the
avidin-biotin peroxidase conjugate method. DNA was isolated
from the same formalin-fixed, paraffin-embedded tissue sections.
Real-time PCR was used to quantify gene amplification. Gene
amplification was analyzed using internal control and classified
as positive if the ratio was more than two. Immunostaining was
classified as 0, 1+, 2+, or 3+. RESULTS: 12/27 tumors showed
gene amplification. Only one tumor showed 3+ HER-2 positivity
and another 1+ positivity as analysed by immunohistochemistry.
The highest levels of DNA amplification corresponded to 3+ and
1+ positivity. CONCLUSION: HER-2 gene amplification data
in pancreatic cancers did not correspond with the immunohisto-
chemical detection. In contrast to the low number of HER-2 positive
cases by immunohistochemistry, RT-PCR showed amplification
of the gene in a high number of cases. Further analysis is required
to explain the discrepancy between the results of the methods,
especially since HER-2-overexpressing pancreatic cancers might
be a target of Herceptin therapy.
46 RAPAMYCIN-INDUCED ENDOTHELIAL CELL
DEATH AND TUMOR VESSEL THROMBOSIS OPTIMIZES
GEMCITABINE’S CYTOTOXIC EFFECT AGAINST
PANCREATIC CANCER
Bruns CJ3, Guba M1, Ko¨hl G2, Yezhelyev M1, Jauch KWS1,
(1) Surgery, University of Munich-Großhadern, Munich, Germany;
(2) Surgery, University of Regensburg, Regensburg, Germany;
(3) Department of Surgery, University of Munich-Großhadern,
Munich Germany
INTRODUCTION AND AIM: Despite current chemotherapies
pancreatic cancer steadfastly remains refractory to treatment. Here
we tested a new approach of combining antiangiogenic and standard
cytotoxic therapy in a metastatic human pancreatic cancer nude
mouse model. PATIENTS AND METHODS: Nude athymic mice
were injected orthotopically with metastatic human L3.6pl cancer
cells. Pancreatic tumors were allowed to become established for
8 days before initiation of rapamycin or gemcitabine treatment.
Standard doses of rapamycin (1.5 mg/kg/d) and gemcitabine
(100 mg/kg, 2x/week) were used in the first group of experiments,
and all animals were sacrificed 28 days after tumor cell injection.
Immunohistochemical analysis was performed from primary
pancreatic tumors for proliferation (Ki67), cell death (TUNEL), and
apoptotic endothelial cells (CD31/TUNEL). To directly test the
effect of rapamycin on tumor blood vessel flow dynamics, L3.6pl
tumor cells were implanted into dorsal skin-fold chambers and
vessels were examined by intravital microscopy on day 7. FACS
analysis of HUVE cells was performed to detect annexin-V-positive
cells. RESULTS: Following orthotopic tumor cell injection, rapa-
mycin treatment alone reduced tumor volume 2-fold more than the
standard gemcitabine therapy. Furthermore, when rapamycin and
gemcitabine treatment were combined, tumors grew to only 19% of
the size observed with gemcitabine treatment alone. Interestingly,
histologic analysis revealed tumor vessel endothelium detachment
and thrombosis with rapamycin treatment. Angiogenesis observation
in dorsal skin-fold chambers after rapamycin treatment directly
illustrated unusually dilated tumor vessels that were highly sus-
ceptible to thrombosis. Furthermore, when we photodynamically
promoted vascular thrombosis in tumors, blood flow was very rapidly
blocked by thrombosis in rapamycin-treated mice, compared to
controls as monitored by intravital microscopy. Furthermore, CD31/
TUNEL staining of orthotopic tumors demonstrated apoptotic
endothelial cells with rapamycin treatment, which was substantiated
in vitro by increased annexin-V staining of rapamycin-treated human
endothelial cells. In contrast, gemcitabine showed no antiangiogenic
effects, but induced extensive tumor cell apoptosis in vivo, albeit
without concomitantly reducing cell proliferation. CONCLUSION:
Our data suggest that rapamycin’s antiangiogenic activity inhibits
tumor expansion, thereby more positively balancing the potent
cytotoxic effect of gemcitabine against tumor progression. Further-
more, our study provides the first evidence that tumor control
achieved with rapamycin is related to tumor vessel thrombosis
associated with the death of endothelial cells. Rapamycin promotion
of thrombosis preferentially in new pancreatic tumor vessels intro-
duces a novel mechanism potentially contributing to its anticancer
action.
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